<SEC-DOCUMENT>0001193125-26-016549.txt : 20260120
<SEC-HEADER>0001193125-26-016549.hdr.sgml : 20260120
<ACCEPTANCE-DATETIME>20260120160359
ACCESSION NUMBER:		0001193125-26-016549
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20260120
DATE AS OF CHANGE:		20260120

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Erasca, Inc.
		CENTRAL INDEX KEY:			0001761918
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				831217027
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-289537
		FILM NUMBER:		26542802

	BUSINESS ADDRESS:	
		STREET 1:		3115 MERRYFIELD ROW
		STREET 2:		THIRD FLOOR
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
		BUSINESS PHONE:		(858) 465-6511

	MAIL ADDRESS:	
		STREET 1:		3115 MERRYFIELD ROW
		STREET 2:		THIRD FLOOR
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92121
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d63320d424b5.htm
<DESCRIPTION>424B5
<TEXT>
<HTML><HEAD>
<TITLE>424B5</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial"><FONT COLOR="#8b3f4e"><B>The information in this preliminary prospectus supplement and the accompanying prospectus is
not complete and may be changed. A registration statement relating to the securities has been declared effective by the Securities and Exchange Commission. This preliminary prospectus supplement and the accompanying prospectus are not an offer to
sell these securities and are not soliciting offers to buy these securities in any jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(5)<BR>Registration No. 333-289537 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial"><FONT COLOR="#8b3f4e"><B>SUBJECT TO COMPLETION, DATED JANUARY&nbsp;20, 2026 </B></FONT></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Preliminary prospectus supplement </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>(To prospectus dated August&nbsp;22,
2025) </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><B><I>$150,000,000 </I></B></P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:2%; text-indent:-2%">


<IMG SRC="g63320g63r02.jpg" ALT="LOGO" STYLE="width:2.30727in;height:0.386263in;">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><B><I>Common stock </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are offering
$150.0&nbsp;million of our common stock. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#8220;ERAS.&#8221; On January&nbsp;16,
2026, the last reported sale price for our common stock on the Nasdaq Global Select Market was $9.62 per share of common stock. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are an &#8220;emerging growth
company&#8221; as that term is used in the Jumpstart Our Business Startups Act of 2012 and, as such, have elected to comply with certain reduced public company disclosure and reporting requirements. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000;">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000;">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="BORDER-BOTTOM:1px solid #000000;"><B>Per&nbsp;share</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="BORDER-BOTTOM:1px solid #000000;"><B>Total</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">$</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">$</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Underwriting discounts and commissions<SUP STYLE="font-size:75%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">$</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top">$</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Proceeds to Erasca, Inc., before expenses</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">$</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">$</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;" ALIGN="right">&#8195;&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See the section titled &#8220;Underwriting&#8221; for a description of the compensation payable to the underwriters. </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We
have granted the underwriters an option to purchase up to an additional $22.5&nbsp;million of shares of common stock from us at the public offering price, less underwriting discounts and commissions, within 30 days from the date of this prospectus
supplement. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Investing in our common stock involves a high degree of risk. See &#8220;<A HREF="#supptoc63320_3">Risk factors</A>&#8221; beginning on page <FONT
STYLE="white-space:nowrap">S-4</FONT> of this prospectus supplement, on page 5 of the accompanying prospectus and the documents incorporated by reference into this prospectus supplement and the accompanying prospectus. </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus
supplement or the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriters expect to deliver
the shares of common stock to purchasers on or about January &#8195;, 2026. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:16pt" ALIGN="center">


<TR>

<TD WIDTH="26%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="24%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="23%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:16pt">
<TD VALIGN="top"><B>J.P. Morgan</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Morgan&nbsp;Stanley</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:16pt; font-family:arial" ALIGN="right"><B>Jefferies</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><B>Evercore ISI</B></TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:9pt; font-family:arial"><B>&#8195;&#8195;&#8195;, 2026 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Prospectus supplement</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#supptoc63320_1">ABOUT THIS PROSPECTUS SUPPLEMENT</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">S-ii</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#supptoc63320_2">PROSPECTUS SUPPLEMENT SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#supptoc63320_3">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">S-4</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#supptoc63320_4">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">S-6</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#supptoc63320_5">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">S-7</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#supptoc63320_6">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">S-8</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#supptoc63320_6a">MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">S-10</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#supptoc63320_7">UNDERWRITING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">S-14</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#supptoc63320_8">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">S-29</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#supptoc63320_9">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">S-29</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#supptoc63320_10">WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"><FONT STYLE="white-space:nowrap">S-30</FONT></TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Prospectus</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#supptoc63320_11">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#supptoc63320_12">WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#supptoc63320_13">THE COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#supptoc63320_14">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#supptoc63320_15">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#supptoc63320_16">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#supptoc63320_18">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#supptoc63320_19">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#supptoc63320_20">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#supptoc63320_21">DESCRIPTION OF UNITS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#supptoc63320_22">GLOBAL SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#supptoc63320_23">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#supptoc63320_24">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#supptoc63320_25">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Neither we nor any of the underwriters have authorized anyone to provide information different from that contained in this prospectus supplement. When you make a
decision about whether to invest in our common stock, you should not rely upon any information other than the information in this prospectus supplement. Neither the delivery of this prospectus supplement nor the sale of shares of our common stock
means that information contained in this prospectus supplement is correct after the date of this prospectus supplement. This prospectus supplement is not an offer to sell or solicitation of an offer to buy shares of our common stock in any
circumstances under which the offer or solicitation is unlawful. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="supptoc63320_1"></A>About this prospectus supplement </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This prospectus supplement and the accompanying prospectus dated August&nbsp;22, 2025 are part of a registration statement that we filed with the Securities and Exchange
Commission (SEC), utilizing a &#8220;shelf&#8221; registration process. This prospectus supplement and the accompanying prospectus relate to the offer by us of shares of our common stock to certain investors. We provide information to you about this
offering of shares of our common stock in two separate documents that are bound together: (1)&nbsp;this prospectus supplement, which describes the specific details regarding this offering; and (2)&nbsp;the accompanying prospectus, which provides
general information, some of which may not apply to this offering. Generally, when we refer to this &#8220;prospectus,&#8221; we are referring to both documents combined. If information in this prospectus supplement is inconsistent with the
accompanying prospectus, you should rely on this prospectus supplement. However, if any statement in one of these documents is inconsistent with a statement in another document having a later date&#8212;for example, a document incorporated by
reference in this prospectus supplement or the accompanying prospectus&#8212;the statement in the document having the later date modifies or supersedes the earlier statement as our business, financial condition, results of operations and prospects
may have changed since the earlier dates. You should read this prospectus supplement, the accompanying prospectus, the documents and information incorporated by reference in this prospectus supplement and the accompanying prospectus, and any free
writing prospectus that we have authorized for use in connection with this offering when making your investment decision. You should also read and consider the information in the documents we have referred you to under the headings &#8220;Where you
can find more information; incorporation by reference.&#8221; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">You should rely only on information contained in or incorporated by reference into this prospectus
supplement and the accompanying prospectus or any free writing prospectus prepared by or on behalf of us or to which we have referred you. We have not, and the underwriters have not, authorized anyone to provide you with information that is
different. We are offering to sell and seeking offers to buy shares of our common stock only in jurisdictions where offers and sales are permitted. The information contained in this prospectus supplement, the accompanying prospectus, the documents
and information incorporated by reference in this prospectus supplement and the accompanying prospectus, and any free writing prospectus that we have authorized for use in connection with this offering are accurate only as of their respective dates,
regardless of the time of delivery of this prospectus supplement or of any sale of our common stock. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In this prospectus supplement, unless the context otherwise
indicates, the terms &#8220;Erasca,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our&#8221; and &#8220;us&#8221; or similar terms refer to Erasca, Inc. and its subsidiaries. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We use our trademarks in this prospectus supplement as well as trademarks, tradenames and service marks that are the property of other organizations. Solely for
convenience, trademarks and tradenames referred to in this prospectus supplement appear without the <SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and <SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> symbols, but those
references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner will not assert its rights, to these trademarks and tradenames. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="supptoc63320_2"></A>Prospectus supplement summary </B></P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>The items in the following summary are described in more detail later in or incorporated by reference into this prospectus supplement and in the accompanying
prospectus. This summary provides an overview of selected information and does not contain all the information you should consider before investing in our common stock. Therefore, you should read the entire prospectus supplement, the accompanying
prospectus and any free writing prospectus that we have authorized for use in connection with this offering carefully, including the &#8220;Risk factors&#8221; section, and other documents or information included or incorporated by reference in this
prospectus supplement and the accompanying prospectus before making any investment decision. </I></P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Company overview </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven
cancers. Molecular alterations in RAS, the&nbsp;most frequently mutated oncogene, and the MAPK pathway, one of the most frequently altered signaling pathways in cancer, account for more than five million new patients diagnosed with cancer globally
each year. Our company was <FONT STYLE="white-space:nowrap">co-founded</FONT> by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK pathway
for the treatment of patients with cancer. Our focused RAS/MAPK pipeline comprises modality-agnostic programs aligned with our three therapeutic strategies of: (1)&nbsp;targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway;
(2)&nbsp;targeting RAS directly; and (3)&nbsp;targeting escape routes that emerge in response to treatment. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our pipeline enables us to pursue a systematic,
data-driven, portfolio-wide clinical development effort to identify therapeutic approaches with the goal of prolonging survival in numerous patient populations with high unmet medical needs. Our modality-agnostic approach aims to allow us to
selectively and potently target critical signaling nodes with the most appropriate modality, including small and large molecule therapeutics. Our purpose-built pipeline includes three clinical-stage programs (ERAS-0015, a <FONT
STYLE="white-space:nowrap">pan-RAS</FONT> molecular glue; ERAS-4001, a <FONT STYLE="white-space:nowrap">pan-KRAS</FONT> inhibitor; and naporafenib, a <FONT STYLE="white-space:nowrap">pan-RAF</FONT> inhibitor), and
<FONT STYLE="white-space:nowrap">ERAS-12,</FONT> a discovery-stage program (an EGFR D2/D3 biparatopic antibody). We believe our world-class team&#8217;s capabilities and experience, further guided by our scientific advisory board, which includes the
world&#8217;s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Recent developments </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The latest updates on the clinical progress for our RAS-targeting franchise and 2026-2027 milestones are as follows: </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>ERAS-0015 &#8211; Potential best-in-class RAS targeting molecule </I></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Dose escalation in AURORAS-1, our ongoing open-label, Phase 1 clinical trial of ERAS-0015 in patients with RAS-mutant solid
tumors, has advanced faster than anticipated, due to significant unmet medical need and high investigator and patient enthusiasm. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></FONT></TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We have observed ongoing confirmed and unconfirmed responses in multiple patients with differing tumor types and RAS
mutations.* </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></FONT></TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We have observed ongoing responses (two confirmed partial responses (&#8220;PRs&#8221;) and one unconfirmed PR) in patients
with different tumor types and RAS mutations achieved at a low dose of 8 mg QD (once per day).* </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Additional ongoing unconfirmed responses observed in patients at doses above 8 mg QD.* </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Favorable safety and tolerability, with no dose-limiting toxicities and predominantly low-grade adverse events observed at
all dose levels evaluated.* </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Well-behaved, linear pharmacokinetics (&#8220;PK&#8221;) across all dose levels evaluated with no observed evidence of
exposure plateau.* </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Subsequent to the cut-off date, we have dosed patients at 40 mg QD. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Anticipated Milestones: </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></FONT></TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Initial Phase 1 monotherapy data in patients with RAS-mutant solid tumors planned for the first half of 2026;**
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></FONT></TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Initiation of monotherapy expansion cohorts and combination dose escalation cohorts planned for the second half of 2026;
and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></FONT></TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Monotherapy expansion data and combination dose escalation data planned for 2027.** </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I></I><B></B><I>ERAS-4001 &#8211; Potential first-in-class pan-KRAS inhibitor</I><B><I></I></B><I> </I></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Dose escalation in BOREALIS-1, our ongoing open-label Phase 1 clinical trial of ERAS-4001 in patients with RAS-mutant solid
tumors, continues to advance as expected. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Anticipated Milestones: </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></FONT></TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Initial Phase 1 monotherapy data in patients with KRAS-mutant solid tumors planned for the second half of 2026; and**
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:ARIAL"><FONT STYLE="FONT-SIZE:95%">&#9675;</FONT></FONT></TD>
<TD WIDTH="2%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Initiation of monotherapy expansion cohorts and combination dose escalation cohorts planned for 2027.
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="2%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Data cutoff date was January 7, 2026 </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left"><B>**</B></TD>
<TD WIDTH="2%" VALIGN="top" >&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><B></B>Topline safety, tolerability, PK, and initial efficacy data </TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Preliminary financial update </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of December&nbsp;31, 2025, our cash, cash equivalents and marketable securities were approximately $341.8&nbsp;million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The cash, cash equivalents and marketable securities information above is based on preliminary unaudited information and management estimates for the year ended
December&nbsp;31, 2025, is not a comprehensive statement of our financial results as of and for the fiscal year ended December&nbsp;31, 2025, and is subject to completion of our financial closing procedures. Our actual cash, cash equivalents and
marketable securities as of December&nbsp;31, 2025 may different from this amount after we complete from our comprehensive accounting procedures for the year ended December&nbsp;31, 2025. Our financial statements for the year ended December&nbsp;31,
2025 will not be available until after this offering is completed, and consequently will not be available to you prior to investing in this offering. Our independent registered public accounting firm has not conducted an audit or review of, and does
not express an opinion or any other form of assurance with respect to, this preliminary estimate. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Corporate information </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We were incorporated under the laws of the state of Delaware on July&nbsp;2, 2018. Our principal executive offices are located at 3115 Merryfield Row, Suite 300, San
Diego, California 92121, and our telephone number is (858) <FONT STYLE="white-space:nowrap">465-6511.</FONT> Our website address is www.erasca.com. The information on, or accessible through, our website is not part of, and is not incorporated into,
this prospectus supplement or the accompanying prospectus and should not be considered part of this prospectus supplement or the accompanying prospectus.<B> </B> </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>The offering </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="33%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial"><B>Common stock offered by us </B></P></TD>
<TD>$150.0&nbsp;million of shares </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="33%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial"><B>Option to purchase additional shares </B></P></TD>
<TD>We have granted the underwriters an option exercisable for a period of 30&nbsp;days after the date of this prospectus supplement to purchase up to an additional $22.5&nbsp;million of shares of our common stock. </TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="33%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial"><B>Common stock to be outstanding immediately after this offering </B></P></TD>
<TD>&#8195;&#8195;&#8195;shares (or &#8195;&#8195;&#8195;shares if the underwriters exercise in full their option to purchase additional shares) </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="33%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial"><B>Use of proceeds </B></P></TD>
<TD>We intend to use the net proceeds from this offering, together with our existing cash, cash equivalents and marketable securities, to fund the research and development of our product candidates and other development programs and for working
capital and other general corporate purposes. We may also use a portion of the remaining net proceeds and our existing cash, cash equivalents and marketable securities, to <FONT STYLE="white-space:nowrap">in-license,</FONT> acquire, or invest in
complementary business, technologies, products or assets; however, we have no current commitments or obligations to do so. See &#8220;Use of proceeds.&#8221; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="33%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial"><B>Risk factors </B></P></TD>
<TD>You should read the &#8220;Risk factors&#8221; section of this prospectus supplement and in the documents incorporated by reference in this prospectus supplement for a discussion of factors to consider before deciding to invest in our common
stock. </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Nasdaq Global Select Market symbol </B></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="33%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"></TD></TR></TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:33%; font-size:10pt; font-family:arial">&#8220;ERAS&#8221; </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The number of shares of common stock to be outstanding immediately after this offering is based on 283,711,805 shares of our common stock outstanding as of
September&nbsp;30, 2025. The number of shares outstanding as of September&nbsp;30, 2025 excludes: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">47,726,901 shares of common stock issuable upon the exercise of options outstanding as of September&nbsp;30, 2025, at a
weighted average exercise price of $3.24 per share; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">17,519,269 shares of common stock reserved for future issuance under our 2021 Incentive Award Plan and our 2021 Employee
Stock Purchase Plan as of September&nbsp;30, 2025. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Except as otherwise indicated, all information in this prospectus supplement assumes
(i)&nbsp;no exercise of outstanding options and (ii)&nbsp;no exercise by the underwriters of their option to purchase up to an additional $22.5&nbsp;million of shares of our common stock. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, the number of shares of our common stock to be outstanding immediately after this offering as shown above does not include the $200&nbsp;million of shares
of our common stock that remain available </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">for sale at September&nbsp;30, 2025 under the Amended and Restated Open Market Sale Agreement<SUP
STYLE="font-size:75%; vertical-align:top">SM</SUP> (the Sales Agreement), with Jefferies LLC, dated August&nbsp;12, 2025. Between September&nbsp;30, 2025 and the date of this prospectus supplement, we have not sold any shares of our common stock
under the Sales Agreement. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="supptoc63320_3"></A>Risk factors </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>You should consider carefully the risks described below and discussed under the section captioned &#8220;Risk Factors&#8221; contained in our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2024 as updated by our subsequent filings under the Securities Exchange Act of 1934, as amended (the Exchange Act), which are incorporated by reference in this prospectus
supplement and the accompanying prospectus in their entirety, together with other information in this prospectus supplement, the accompanying prospectus and the information and documents incorporated by reference in this prospectus supplement and
the accompanying prospectus, and any free writing prospectus that we have authorized for use in connection with this offering before you make a decision to invest in our common stock. If any of the following events actually occur, our business,
operating results, prospects or financial condition could be materially and adversely affected. This could cause the trading price of our common stock to decline, and you may lose all or part of your investment. The risks described below are not the
only ones that we face. Additional risks not presently known to us or that we currently deem immaterial may also affect our business operations. </I></P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks
relating to this offering </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If you purchase shares of our common stock sold in this offering, you will experience immediate and substantial dilution in the
net tangible book value of your shares. In addition, we may issue additional equity or convertible debt securities in the future, which may result in additional dilution to investors. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The offering price per share of common stock in this offering is considerably more than the net tangible book value per share of our outstanding common stock. As a
result, investors purchasing shares of common stock in this offering will pay a price per share that substantially exceeds the value of our tangible assets after subtracting liabilities. Based upon the offering price of
$&#8195;&#8195;&#8195;&#8195;per share, new investors will incur immediate dilution of $&#8195;&#8195;&#8195;&#8195;per share based on the net tangible book value as of September&nbsp;30, 2025. For a more detailed discussion of the foregoing, see
&#8220;Dilution.&#8221; To the extent outstanding stock options are exercised, there will be further dilution to new investors. In addition, to the extent we need to raise additional capital in the future and we issue additional shares of common
stock or securities convertible or exchangeable for our common stock, our then existing stockholders may experience dilution and the new securities may have rights senior to those of our common stock offered in this offering. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, pursuant to the Sales Agreement, we may issue and sell from time to time through Jefferies LLC shares of our common stock, in an aggregate amount not to
exceed $200&nbsp;million. As of the date of this prospectus supplement, $200&nbsp;million of common stock remains available for sale under the Sales Agreement. To the extent that we sell additional shares of our common stock pursuant to the Sales
Agreement subsequent to this offering, investors purchasing securities in this offering could experience further dilution. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We have broad discretion in the use
of the net proceeds from this offering and may not use them effectively. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our management will have broad discretion in the application of the net proceeds
from this offering, including for any of the purposes described in &#8220;Use of proceeds,&#8221; and you will not have the opportunity as part of your investment decision to assess whether the net proceeds are being used appropriately. Because of
the number and variability of factors that will determine our use of the net proceeds from this offering, their ultimate use may vary substantially from their currently intended use. Our management might not apply our net proceeds in ways that
ultimately increase the value of your investment. We expect to use the net proceeds from this offering, together with our existing cash, cash equivalents and marketable securities, to fund the research and development of our product candidates and
other development programs and for working capital and general corporate purposes. We may also use a portion of the remaining net proceeds and our existing cash, cash equivalents and marketable securities, to
<FONT STYLE="white-space:nowrap">in-license,</FONT> acquire, or invest in complementary businesses, technologies, products or assets; however, we have no current commitments or obligations to do so. The failure by our management to apply these funds
effectively could </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
harm our business. Pending their use, we may invest the net proceeds from this offering in short- and intermediate-term, investment-grade, interest-bearing securities. These investments may not
yield a favorable return to our stockholders. If we do not invest or apply the net proceeds from this offering in ways that enhance stockholder value, we may fail to achieve expected financial results, which could cause our stock price to decline.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="supptoc63320_4"></A>Cautionary note regarding forward-looking statements </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This prospectus supplement and the accompanying prospectus, including the documents incorporated by reference herein and therein, and any free writing prospectus that we
have authorized for use in connection with this offering contain forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended (the Securities Act), and Section&nbsp;21E of the Exchange Act. All
statements other than statements of historical facts contained in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein are forward-looking statements, including statements regarding
our future results of operations and financial position, business strategy, research and development plans, the anticipated timing, costs, design and conduct of our ongoing and planned preclinical studies and planned clinical trials for our product
candidates, the timing and likelihood of regulatory filings and approvals for our product candidates, our ability to commercialize our product candidates, if approved, the pricing and reimbursement of our product candidates, if approved, the
potential to develop future product candidates, the potential benefits of current and future licenses, acquisitions and strategic arrangements with third parties, and our intent to enter into any future strategic arrangements, the timing and
likelihood of success, plans and objectives of management for future operations, and future results of anticipated product development efforts and the anticipated use of proceeds from this offering, are forward-looking statements. These statements
involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the
forward-looking statements. This prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein also contain estimates and other statistical data made by independent parties and by us relating to
market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and estimates of our future
performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In some cases, you can
identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221;
&#8220;project,&#8221; &#8220;contemplates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions. The
forward-looking statements in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference herein and therein are only predictions. We have based these forward-looking statements largely on our current
expectations and projections about future events and financial trends that we believe may affect our business, financial condition and results of operations. These forward-looking statements speak only as of the date of this prospectus supplement
and are subject to a number of risks, uncertainties and assumptions, which we discuss in greater detail in the documents incorporated by reference herein, including under the heading &#8220;Risk factors&#8221; and elsewhere in this prospectus
supplement. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in an evolving
environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties. Given these risks and uncertainties, you should not place undue reliance on these
forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained in this prospectus supplement, the accompanying prospectus or the documents incorporated by
reference herein and therein, whether as a result of any new information, future events, changed circumstances or otherwise. For all forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in
the Private Securities Litigation Reform Act of 1995. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="supptoc63320_5"></A>Use of proceeds </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We estimate that we will receive net proceeds of approximately $&#8195;&#8195;&#8195;&#8195;million from the sale of &#8195;&#8195;&#8195;&#8195;shares of common stock
offered by us in this offering, or approximately $&#8195;&#8195;&#8195;&#8195;million if the underwriters exercise in full their option to purchase up to an additional&#8195;&#8195;&#8195;&#8195;shares of common stock, after deducting the estimated
underwriting discounts and commissions and estimated offering expenses payable by us. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We intend to use the net proceeds from this offering, together with our
existing cash, cash equivalents and marketable securities, to fund the research and development of our product candidates and other development programs and for working capital and other general corporate purposes. We may also use a portion of the
remaining net proceeds, together with our existing cash, cash equivalents and marketable securities, to <FONT STYLE="white-space:nowrap">in-license,</FONT> acquire, or invest in complementary businesses, technologies, products or assets; however, we
have no current commitments or obligations to do so. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The amounts and timing of our actual expenditures will depend on numerous factors, including the factors
described under &#8220;Risk factors&#8221; in this prospectus supplement and in the documents incorporated by reference herein, as well as the amount of cash used in our operations. We may find it necessary or advisable to use the net proceeds for
other purposes, and we will have broad discretion in the application of the net proceeds. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pending the uses described above, we plan to invest the net proceeds from
this offering in short- and intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="supptoc63320_6"></A>Dilution </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If you invest in our common stock or in this offering, your interest will be diluted to the extent of the difference between the offering price per share and the as
adjusted net tangible book value per share of our common stock immediately after this offering. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of September&nbsp;30, 2025, our net tangible book value was
approximately $347.9&nbsp;million, or approximately $1.23 per share of common stock, based on 283,711,805 shares of our common stock outstanding. Our net tangible book value per share is equal to our total tangible assets, less our total
liabilities, divided by the total number of shares of our common stock outstanding as of September&nbsp;30, 2025. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">After giving effect to our sale in this offering
of&#8195;&#8195;&#8195;&#8195;shares of our common stock at the offering price of $&#8195;&#8195;&#8195;&#8195;per share and after deducting the underwriting discounts and commissions and estimated offering expenses payable by us, our as adjusted
net tangible book value as of September&nbsp;30, 2025 would have been approximately $&#8195;&#8195;&#8195;&#8195;million, or approximately $&#8195;&#8195;&#8195;&#8195;per share of our common stock. This represents an immediate decrease in net
tangible book value of approximately $&#8195;&#8195;&#8195;&#8195;per share to our existing stockholders and an immediate dilution of $&#8195;&#8195;&#8195;&#8195;per share to new investors purchasing our common stock in this offering. The following
table illustrates this per share dilution to the new investors purchasing shares of our common stock. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:2.00pt solid #000000;"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Public offering price per share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000;">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000;">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000;" ALIGN="right">&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net tangible book value per share as of September&nbsp;30, 2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Decrease in net tangible book value per share attributable to this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">As adjusted net tangible book value per share, after giving effect to this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Dilution in net tangible book value per share to new investors in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If the underwriters exercise their option in full to purchase up to an additional&#8195;&#8195;&#8195;&#8195; shares of our common stock
at the public offering price of $&#8195;&#8195;&#8195;&#8195;per share, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us, our as adjusted net tangible book value after this offering would be
approximately $&#8195;&#8195;&#8195;&#8195;per share, representing an immediate decrease in net tangible book value of approximately $&#8195;&#8195;&#8195;&#8195;per share to our existing stockholders and immediate dilution of approximately
$&#8195;&#8195;&#8195;&#8195; per share to new investors purchasing common stock in this offering. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The foregoing table and calculations (other than net tangible
book value calculations) are based on 283,711,805 shares of our common stock outstanding as of September&nbsp;30, 2025. The number of shares outstanding as of September&nbsp;30, 2025 excludes: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">47,726,901 shares of common stock issuable upon the exercise of options outstanding as of September&nbsp;30, 2025, at a
weighted average exercise price of $3.24 per share; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">17,519,269 shares of common stock reserved for future issuance under our 2021 Incentive Award Plan and our 2021 Employee
Stock Purchase Plan as of September&nbsp;30, 2025. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Except as otherwise indicated, all information in this prospectus supplement assumes
(i)&nbsp;no exercise of outstanding options and (ii)&nbsp;no exercise by the underwriters of their option to purchase up to an additional $22.5&nbsp;million of shares of our common stock. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To the extent that outstanding options are exercised, you may experience further dilution. In addition, we may choose to raise additional capital due to market
conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. To the extent that we raise additional capital by issuing equity or convertible debt securities, your ownership will be
further diluted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, the number of shares of our common stock to be outstanding immediately after this offering as shown above
does not include the $200.0&nbsp;million of shares of our common stock that remain available for sale at September&nbsp;30, 2025 under the Sales Agreement. Between September&nbsp;30, 2025 and the date of this prospectus supplement, we have not sold
any shares of our common stock under the Sales Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="supptoc63320_6a"></A>Material U.S. federal income tax consequences to
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following discussion is a summary of the material U.S. federal income tax consequences to <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders (as defined below) of the purchase, ownership, and disposition of our common stock issued pursuant to this offering, but does not purport to be a complete analysis of all potential tax effects. The
effects of other U.S. federal tax laws, such as estate and gift tax laws, and any applicable state, local or <FONT STYLE="white-space:nowrap">non-U.S.</FONT> tax laws are not discussed. This discussion is based on the U.S. Internal Revenue Code of
1986, as amended (the &#8220;Code&#8221;), U.S. Treasury regulations promulgated thereunder (the &#8220;Treasury Regulations&#8221;), judicial decisions, and published rulings and administrative pronouncements of the U.S. Internal Revenue Service
(the &#8220;IRS&#8221;), in each case in effect as of the date hereof. These authorities may change or be subject to differing interpretations. Any such change or differing interpretation may be applied retroactively in a manner that could adversely
affect a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder. We have not sought and will not seek any rulings from the IRS regarding the matters discussed below. There can be no assurance the IRS or a court will not take a contrary position to
that discussed below regarding the tax consequences of the purchase, ownership, and disposition of our common stock. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This discussion is limited to <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders that hold our common stock as a &#8220;capital asset&#8221; within the meaning of Section&nbsp;1221 of the Code (generally, property held for investment). This discussion does not address all U.S.
federal income tax consequences relevant to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#8217;s particular circumstances, including the impact of the Medicare contribution tax on net investment income and the alternative minimum tax.
In addition, it does not address consequences relevant to <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders subject to special rules, including, without limitation: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">U.S. expatriates and former citizens or long-term residents of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">persons holding our common stock as part of a hedge, straddle, or other risk reduction strategy or as part of a conversion
transaction or other integrated investment; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">banks, insurance companies, and other financial institutions; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">brokers, dealers, or traders in securities or currencies; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">&#8220;controlled foreign corporations,&#8221; &#8220;foreign controlled foreign corporations,&#8221; &#8220;passive
foreign investment companies,&#8221; and corporations that accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">partnerships or other entities or arrangements treated as partnerships for U.S. federal income tax purposes (and investors
therein); </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations or governmental organizations; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">persons deemed to sell our common stock under the constructive sale provisions of the Code; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">persons who hold or receive our common stock pursuant to the exercise of any employee stock option or otherwise as
compensation; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plans; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">&#8220;qualified foreign pension funds&#8221; as defined in Section&nbsp;897(l)(2) of the Code and entities all of the
interests of which are held by qualified foreign pension funds; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">persons subject to special tax accounting rules as a result of any item of gross income with respect to the stock being
taken into account in an applicable financial statement. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If an entity treated as a partnership for U.S. federal income tax purposes holds our
common stock, the tax treatment of a partner in the partnership will depend on the status of the partner, the activities of the partnership, and certain determinations made at the partner level. Accordingly, partnerships holding our common stock and
the partners in such partnerships should consult their tax advisors regarding the U.S. federal income tax consequences to them. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT TAX ADVICE. INVESTORS SHOULD CONSULT THEIR TAX
ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S. FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF OUR COMMON STOCK ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT
TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL OR <FONT STYLE="white-space:nowrap">NON-U.S.</FONT> TAXING JURISDICTION, OR UNDER ANY APPLICABLE INCOME TAX TREATY. </B></P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Definition of a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For
purposes of this discussion, a <FONT STYLE="white-space:nowrap">&#8220;Non-U.S.</FONT> Holder&#8221; is any beneficial owner of our common stock that is neither a &#8220;U.S. person&#8221; nor an entity treated as a partnership for U.S. federal
income tax purposes. A U.S. person is any person that, for U.S. federal income tax purposes, is or is treated as any of the following: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a corporation created or organized under the laws of the United States, any state thereof, or the District of Columbia;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a trust that (1)&nbsp;is subject to the primary supervision of a U.S. court and the control of one or more &#8220;United
States persons&#8221; (within the meaning of Section&nbsp;7701(a)(30) of the Code), or (2)&nbsp;has a valid election in effect to be treated as a United States person for U.S. federal income tax purposes. </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Distributions </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We do not intend to pay cash dividends to our stockholders in
the foreseeable future. However, if we do make distributions of cash or property on our common stock, such distributions will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and
profits, as determined under U.S. federal income tax principles. Amounts not treated as dividends for U.S. federal income tax purposes will constitute a return of capital and first be applied against and reduce a
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#8217;s adjusted tax basis in its common stock, but not below zero. Any excess will be treated as capital gain and will be treated as described below under &#8220;&#8212;Sale or other taxable
disposition.&#8221; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Subject to the discussion below on effectively connected income, dividends paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder
will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends (or such lower rate specified by an applicable income tax treaty, provided the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder furnishes a
valid IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> or <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (or other applicable documentation) certifying qualification for the lower treaty rate). A <FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that does not timely furnish the required documentation, but that qualifies for a reduced treaty rate, may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for
refund with the IRS. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding their entitlement to benefits under any applicable income tax treaty. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If dividends paid to a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder are effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
Holder&#8217;s conduct of a trade or business within the United States (and, if required by an applicable income tax treaty, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains a permanent establishment in the United States to
which such dividends are attributable), the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will be exempt from the U.S. federal withholding tax described above. To claim the exemption, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
Holder must furnish to the applicable withholding agent a valid IRS Form <FONT STYLE="white-space:nowrap">W-8ECI,</FONT> certifying that the dividends are effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#8217;s
conduct of a trade or business within the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any such effectively connected dividends will be subject to U.S. federal income tax on a net income basis at the
regular rates. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on such effectively
connected dividends, as adjusted for certain items. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding any applicable tax treaties that may provide for different rules. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Sale or other taxable disposition </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will not be subject to U.S. federal income tax on any gain realized upon the sale or other taxable disposition of our common stock unless: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#8217;s conduct of a
trade or business within the United States (and, if required by an applicable income tax treaty, the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder maintains a permanent establishment in the United States to which such gain is
attributable); </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder is a nonresident alien individual present in the United States
for 183 days or more during the taxable year of the disposition and certain other requirements are met; or </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our common stock constitutes a U.S. real property interest (&#8220;USRPI&#8221;) by reason of our status as a U.S. real
property holding corporation (&#8220;USRPHC&#8221;) for U.S. federal income tax purposes. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Gain described in the first bullet point above generally
will be subject to U.S. federal income tax on a net income basis at the regular rates. A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder that is a corporation also may be subject to a branch profits tax at a rate of 30% (or such lower rate
specified by an applicable income tax treaty) on such effectively connected gain, as adjusted for certain items. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A <FONT STYLE="white-space:nowrap">Non-U.S.</FONT>
Holder described in the second bullet point above will be subject to U.S. federal income tax at a rate of 30% (or such lower rate specified by an applicable income tax treaty) on gain realized upon the sale or other taxable disposition of our common
stock, which may be offset by U.S. source capital losses of the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder (even though the individual is not considered a resident of the United States), provided the
<FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder has timely filed U.S. federal income tax returns with respect to such losses. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">With respect to the third
bullet point above, we believe we currently are not, and do not anticipate becoming, a USRPHC. Because the determination of whether we are a USRPHC depends, however, on the fair market value of our USRPIs relative to the fair market value of our <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> real property interests and our other business assets, there can be no assurance we currently are not a USRPHC or will not become one in the future. Even if we are or were to become a USRPHC, gain arising
from the sale or other taxable disposition of our common stock by a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder will not be subject to U.S. federal income tax if our common stock is &#8220;regularly traded,&#8221; as defined by
applicable Treasury Regulations, on an established securities market and such <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder owned, actually and constructively, 5% or less of our common stock throughout the shorter of the five-year period
ending on the date of the sale or other taxable disposition or the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#8217;s holding period. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><FONT
STYLE="white-space:nowrap">Non-U.S.</FONT> Holders should consult their tax advisors regarding potentially applicable income tax treaties that may provide for different rules. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Information reporting and backup withholding </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Payments of dividends on our
common stock will not be subject to backup withholding, provided the applicable withholding agent does not have actual knowledge or reason to know the holder is a United States person and the holder either certifies its <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> status, such as by furnishing a valid IRS Form <FONT STYLE="white-space:nowrap">W-8BEN,</FONT> <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or <FONT
STYLE="white-space:nowrap">W-8ECI,</FONT> or otherwise establishes an exemption. However, information returns are required to be filed with the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
IRS in connection with any distributions on our common stock paid to the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder, regardless of whether such distributions constitute dividends or
whether any tax was actually withheld. In addition, proceeds of the sale or other taxable disposition of our common stock within the United States or conducted through certain U.S.-related brokers generally will not be subject to backup withholding
or information reporting if the applicable withholding agent receives the certification described above and does not have actual knowledge or reason to know that such holder is a United States person or the holder otherwise establishes an exemption.
Proceeds of a disposition of our common stock conducted through a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> office of a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> broker generally will not be subject to backup withholding or information
reporting. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Copies of information returns that are filed with the IRS may also be made available under the provisions of an applicable treaty or agreement to the tax
authorities of the country in which the <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder resides or is established. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Backup withholding is not an additional
tax. Any amounts withheld under the backup withholding rules may be allowed as a refund or a credit against a <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> Holder&#8217;s U.S. federal income tax liability, provided the required information is
timely furnished to the IRS. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Additional withholding tax on payments made to foreign accounts </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Withholding taxes may be imposed under Sections 1471 to 1474 of the Code (such Sections commonly referred to as the Foreign Account Tax Compliance Act, or
&#8220;FATCA&#8221;) on certain types of payments made to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> financial institutions and certain other <FONT STYLE="white-space:nowrap">non-U.S.</FONT> entities. Specifically, a 30% withholding tax may be
imposed on dividends on, or (subject to the proposed Treasury Regulations discussed below) gross proceeds from the sale or other disposition of, our common stock paid to a &#8220;foreign financial institution&#8221; or a <FONT
STYLE="white-space:nowrap">&#8220;non-financial</FONT> foreign entity&#8221; (each as defined in the Code), unless (1)&nbsp;the foreign financial institution undertakes certain diligence and reporting obligations, (2)&nbsp;the <FONT
STYLE="white-space:nowrap">non-financial</FONT> foreign entity either certifies it does not have any &#8220;substantial United States owners&#8221; (as defined in the Code) or furnishes identifying information regarding each substantial United
States owner, or (3)&nbsp;the foreign financial institution or <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity otherwise qualifies for an exemption from these rules. If the payee is a foreign financial institution and is subject
to the diligence and reporting requirements in clause (1)&nbsp;above, it must enter into an agreement with the U.S. Department of the Treasury requiring, among other things, that it undertake to identify accounts held by certain &#8220;specified
United States persons&#8221; or &#8220;United States owned foreign entities&#8221; (each as defined in the Code), annually report certain information about such accounts, and withhold 30% on certain payments to
<FONT STYLE="white-space:nowrap">non-compliant</FONT> foreign financial institutions and certain other account holders. Foreign financial institutions located in jurisdictions that have an intergovernmental agreement with the United States governing
FATCA may be subject to different rules. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under the applicable Treasury Regulations and administrative guidance, withholding under FATCA generally applies to
payments of dividends on our common stock. While withholding under FATCA would have applied also to payments of gross proceeds from the sale or other disposition of stock on or after January&nbsp;1, 2019, proposed Treasury Regulations eliminate
FATCA withholding on payments of gross proceeds entirely. Taxpayers generally may rely on these proposed Treasury Regulations until final Treasury Regulations are issued. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Prospective investors should consult their tax advisors regarding the potential application of withholding under FATCA to their investment in our common stock. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT TAX ADVICE. INVESTORS SHOULD CONSULT THEIR TAX ADVISORS WITH RESPECT TO THE APPLICATION OF THE U.S.
FEDERAL INCOME TAX LAWS TO THEIR PARTICULAR SITUATIONS AS WELL AS ANY TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF OUR COMMON STOCK ARISING UNDER THE U.S. FEDERAL ESTATE OR GIFT TAX LAWS OR UNDER THE LAWS OF ANY STATE, LOCAL OR <FONT
STYLE="white-space:nowrap">NON-U.S.</FONT> TAXING JURISDICTION, OR UNDER ANY APPLICABLE INCOME TAX TREATY. </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="supptoc63320_7"></A>Underwriting </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are offering the shares of common stock described in this prospectus supplement through a number of underwriters. J.P. Morgan Securities LLC, Morgan
Stanley&nbsp;&amp; Co. LLC, Jefferies LLC and Evercore Group L.L.C. acting as joint <FONT STYLE="white-space:nowrap">book-running</FONT> managers of the offering and as representatives of the underwriters. We have entered into an underwriting
agreement with the underwriters. Subject to the terms and conditions of the underwriting agreement, we have agreed to sell to the underwriters, and each underwriter has severally agreed to purchase, at the public offering price less the underwriting
discounts and commissions set forth on the cover page of this prospectus supplement, the number of shares of common stock listed next to its name in the following table: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000;">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000;"><B>Name</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000;"><B>Number&nbsp;of<BR>shares</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">J.P. Morgan Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Morgan Stanley&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Evercore Group L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="4" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriters are committed to purchase all the shares of common stock offered by us if they purchase any shares. The underwriting
agreement also provides that if an underwriter defaults, the purchase commitments of <FONT STYLE="white-space:nowrap">non-defaulting</FONT> underwriters may also be increased or the offering may be terminated. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriters propose to offer the shares of common stock directly to the public at the initial public offering price set forth on the cover page of this prospectus
supplement and to certain dealers at that price less a concession not in excess of $&#8195;&#8195;&#8195;&#8195; per share. Any such dealers may resell shares to certain other brokers or dealers at a discount of up to $&#8195;&#8195;&#8195;&#8195;
per share from the initial public offering price. After the initial offering of the shares to the public, if all of the shares of common stock are not sold at the initial public offering price, the underwriters may change the offering price and the
other selling terms. Sales of any shares made outside of the United States may be made by affiliates of the underwriters. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriters have an option to buy up
to &#8195;&#8195;&#8195;&#8195; additional shares of common stock from us to cover sales of shares by the underwriters which exceed the number of shares specified in the table above. The underwriters have 30&nbsp;days from the date of this
prospectus supplement to exercise this option to purchase additional shares. If any shares are purchased with this option to purchase additional shares, the underwriters will purchase shares in approximately the same proportion as shown in the table
above. If any additional shares of common stock are purchased, the underwriters will offer the additional shares on the same terms as those on which the shares are being offered. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriting fee is equal to the public offering price per share of common stock less the amount paid by the underwriters to us per share of common stock. The
underwriting fee is $&#8195;&#8195;&#8195;&#8195; per share. The following table shows the per share and total underwriting discounts and commissions to be paid to the underwriters assuming both no exercise and full exercise of the
underwriters&#8217; option to purchase additional shares. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="10%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000;">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000;">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000;">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000;"><B>Without&nbsp;option<BR>to purchase<BR>additional<BR>shares<BR>exercise</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000;"><B>With&nbsp;full&nbsp;option<BR>to purchase<BR>additional<BR>shares<BR>exercise</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000;">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Per Share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#8195;&#8195;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We estimate that the total expenses of this offering, including registration, filing and listing fees, printing fees
and legal and accounting expenses, but excluding the underwriting discounts and commissions, will be approximately $&#8195;&#8195;&#8195;&#8195;. We have agreed to reimburse the underwriters for expenses relating to the clearance of this offering
with the Financial Industry Regulatory Authority, Inc. in an amount up to $25,000. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A prospectus supplement and the accompanying prospectus in electronic format may
be made available on the web sites maintained by one or more underwriters, or selling group members, if any, participating in the offering. The underwriters may agree to allocate a number of shares to underwriters and selling group members for sale
to their online brokerage account holders. Internet distributions will be allocated by the representatives to underwriters and selling group members that may make Internet distributions on the same basis as other allocations. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have agreed that we will not, subject to certain exceptions, (i)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any
option or contract to sell, grant any option, right or warrant to purchase, hedge, lend, or otherwise transfer or dispose of, directly or indirectly, or submit to, or file with, the SEC a registration statement under the Securities Act relating to,
any shares of our common stock or any securities convertible into or exercisable or exchangeable for any shares of our common stock, or (ii)&nbsp;enter into any swap, hedging, or other agreement that transfers, in whole or in part, any of the
economic consequences of ownership of any shares of common stock or any such other securities, or publicly disclose the intention to undertake any of the foregoing in clause (i)&nbsp;or (ii), (regardless of whether any of these transactions are to
be settled by the delivery of shares of common stock or such other securities, in cash or otherwise), in each case without the prior written consent of J.P. Morgan Securities LLC for a period of 60 days after the date of this prospectus supplement,
other than the shares of our common stock to be sold in this offering. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The restrictions on our actions, as described above, do not apply to certain transactions,
including (i)&nbsp;the issuance of shares of common stock or securities convertible into or exercisable for shares of our common stock pursuant to the exercise of warrants or options (including net exercise) or the settlement of restricted stock
units (&#8220;RSUs&#8221;) (including net settlement), in each case outstanding on the date of the underwriting agreement and described in this prospectus supplement, <U>provided</U> that such recipients enter into a
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreement with the underwriters; (ii)&nbsp;grants of stock options, stock awards, restricted stock, RSUs, or other equity awards and the issuance of shares of common stock or securities convertible
into or exercisable or exchangeable for shares of our common stock (whether upon the exercise of stock options or otherwise) to our employees, officers, directors, advisors, or consultants pursuant to the terms of an equity compensation plan in
effect as of the closing date of this offering and described in this prospectus supplement, including our 2021 Employee Stock Purchase Plan, <U>provided</U> that a newly appointed director or executive officer that is such a recipient enter into a <FONT
STYLE="white-space:nowrap">lock-up</FONT> agreement with the underwriters; (iii)&nbsp;the issuance of up to 5% of the outstanding shares of common stock, or securities convertible into, exercisable for, or which are otherwise exchangeable for,
common stock, immediately following the closing date of this offering, in acquisitions or other similar strategic transactions, <U>provided</U> that such recipients enter into a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement with the
underwriters; (iv)&nbsp;the filing of any registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> relating to securities granted or to be granted pursuant to any plan in effect on the date of the underwriting agreement and
described in this prospectus supplement or any assumed benefit plan pursuant to an acquisition or similar strategic transaction; and (v)&nbsp;the issuance by us of shares of common stock in connection with sales under an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">&#8220;at-the-market&#8221;</FONT></FONT> equity offering program pursuant to the Sales Agreement, provided no sales shall be made under the Sale Agreement until the earlier of (a)&nbsp;the
representatives exercising their option to purchase additional shares in full or (b) 30 days after the date of this prospectus supplement. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our directors and
executive officers, and certain of our securityholders (such persons, the <FONT STYLE="white-space:nowrap">lock-up</FONT> parties) have entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters prior to the
commencement of this offering pursuant to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
which each <FONT STYLE="white-space:nowrap">lock-up</FONT> party, with limited exceptions, for a period of 60 days after the date of this prospectus supplement (such period, the restricted
period), may not and may not cause any of their direct or indirect affiliates to, without the prior written consent of J.P. Morgan Securities LLC, (i)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any
option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any shares of our common stock or any securities convertible into or exercisable or exchangeable for our
common stock (including without limitation, our common stock or such other securities which may be deemed to be beneficially owned by the <FONT STYLE="white-space:nowrap">lock-up</FONT> party in accordance with the rules and regulations of the SEC
and securities which may be issued upon exercise of a stock option or warrant) (collectively with the common stock, the <FONT STYLE="white-space:nowrap">lock-up</FONT> securities), (ii) enter into any hedging, swap or other agreement or transaction
that transfers, in whole or in part, any of the economic consequences of ownership of the <FONT STYLE="white-space:nowrap">lock-up</FONT> securities, whether any such transaction described in clause (i)&nbsp;or (ii)&nbsp;above is to be settled by
delivery of the <FONT STYLE="white-space:nowrap">lock-up</FONT> securities, in cash or otherwise, (iii)&nbsp;make any demand for or exercise any right with respect to the registration of any the lock up securities, or (iv)&nbsp;publicly disclose the
intention to do any of the foregoing. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Such persons or entities have further acknowledged that these undertakings preclude them from engaging from engaging in any
hedging or other transactions or arrangements (including, without limitation, any short sale or the purchase or sale of, or entry into, any put or call option, or combination thereof, forward, swap or any other derivative transaction or instrument,
however described or defined) designed or intended, or which could reasonably be expected to lead to or result in, a sale or disposition or transfer (whether by the <FONT STYLE="white-space:nowrap">lock-up</FONT> party or any other person) of any
economic consequences of ownership, in whole or in part, directly or indirectly, of any lock- up securities, whether any such transaction or arrangement (or instrument <U>provided</U> for thereunder) would be settled by delivery of <FONT
STYLE="white-space:nowrap">lock-up</FONT> securities, in cash or otherwise. Such persons or entities further confirm that they have furnished the representatives with the details of any transaction such persons or entities, or any of their
respective affiliates, is a party to as of the date hereof, which transaction would have been restricted by the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements if it had been entered into by such persons or entities during the restricted
period. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The restrictions described in the immediately preceding paragraph and contained in the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements between
the underwriters and the <FONT STYLE="white-space:nowrap">lock-up</FONT> parties do not apply, subject in certain cases to various conditions, to certain transactions, including: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(i)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfers of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities: </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">as a bona fide gift or gifts, including without limitation to a charitable organization or educational institution, or for bona fide estate planning purposes, <U>provided</U> that, such transfer shall not involve a
disposition for value and each donee, devisee, transferee or distributee shall execute and deliver to the representatives a <FONT STYLE="white-space:nowrap">lock-up</FONT> letter in the form of the <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreements, <U>provided further</U> that, no filing by any party (donor, donee, devisee, transferor, transferee, distributer or distributee) under the Exchange Act, or other public announcement shall be required or shall be made voluntarily in
connection with such transfer or distribution (other than a filing on a Form 5 made after the expiration of the restricted period); </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">by will, other testamentary document or intestacy, provided that, such transfer shall not involve a disposition for value and each donee, devisee, transferee or distributee shall execute and deliver to the
representatives a <FONT STYLE="white-space:nowrap">lock-up</FONT> letter in the form of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, <U>provided further</U> that, no filing by any party (donor, donee, devisee, transferor,
transferee, distributer or distributee) under the Exchange Act, or other public announcement shall be required or shall be made voluntarily in connection with such transfer or distribution (other than a filing on a Form 5 made after the expiration
of the restricted period); </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to any member of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party&#8217;s immediate family or to any trust for the direct or indirect benefit of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party or the
immediate family of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party, or if the <FONT STYLE="white-space:nowrap">lock-up</FONT> party is a trust, to a trustor or beneficiary of the trust or to the estate of a beneficiary of such trust (for
purposes of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, &#8220;immediate family&#8221; shall mean any relationship by blood, current or former marriage, domestic partnership or adoption, not more remote than first cousin),
<U>provided</U> that, such transfer shall not involve a disposition for value and each donee, devisee, transferee or distributee shall execute and deliver to the representatives a <FONT STYLE="white-space:nowrap">lock-up</FONT> letter in the form of
the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, provided further that, no filing by any party (donor, donee, devisee, transferor, transferee, distributer or distributee) under the Exchange Act, or other public announcement shall be
required or shall be made voluntarily in connection with such transfer or distribution (other than a filing on a Form 5 made after the expiration of the restricted period); </TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to a partnership, limited liability company or other entity of which the <FONT STYLE="white-space:nowrap">lock-up</FONT> party and the immediate family of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party are
the legal and beneficial owner of all of the outstanding equity securities or similar interests, <U>provided</U> that, such transfer shall not involve a disposition for value and each donee, devisee, transferee or distributee shall execute and
deliver to the representatives a <FONT STYLE="white-space:nowrap">lock-up</FONT> letter in the form of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, <U>provided</U> <U>further</U> that, no filing by any party (donor, donee,
devisee, transferor, transferee, distributer or distributee) under the Exchange Act, or other public announcement shall be required or shall be made voluntarily in connection with such transfer or distribution (other than a filing on a Form 5 made
after the expiration of the restricted period); </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to a nominee or custodian of a person or entity to whom a disposition or transfer would be permissible under clauses (1)&nbsp;through (4), <U>provided</U> that, such transfer shall not involve a disposition for value
and each donee, devisee, transferee or distributee shall execute and deliver to the representatives a <FONT STYLE="white-space:nowrap">lock-up</FONT> letter in the form of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, <U>provided
further</U> that, no filing by any party (donor, donee, devisee, transferor, transferee, distributer or distributee) under the Exchange Act, or other public announcement shall be required or shall be made voluntarily in connection with such transfer
or distribution (other than a filing on a Form 5 made after the expiration of the restricted period); </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if the <FONT STYLE="white-space:nowrap">lock-up</FONT> party is a corporation, partnership, limited liability company, trust or other business entity, (A)&nbsp;to another corporation, partnership, limited liability
company, trust or other business entity that is an affiliate (as defined in Rule 405 promulgated under the Securities Act, as amended) of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party, or to any investment fund or other entity
controlling, controlled by, managing or managed by or under common control with the <FONT STYLE="white-space:nowrap">lock-up</FONT> party or affiliates of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party (including, for the avoidance of
doubt, where the <FONT STYLE="white-space:nowrap">lock-up</FONT> party is a partnership, to its general partner or a successor partnership or fund, or any other funds managed by such partnership), or (B)&nbsp;as part of a distribution, to members or
shareholders of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party, <U>provided</U> that, such transfer shall not involve a disposition for value and each donee, devisee, transferee or distributee shall execute and deliver to the
representatives a <FONT STYLE="white-space:nowrap">lock-up</FONT> letter in the form of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, <U>provided further</U> that, no filing by any party (donor, donee, devisee, transferor,
transferee, distributer or distributee) under the Exchange Act, or other public announcement shall be required or shall be made voluntarily in connection with such transfer or distribution (other than a filing on a Form 5 made after the expiration
of the restricted period); </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">by operation of law, such as pursuant to a qualified domestic order, divorce settlement, divorce decree or separation
agreement, <U>provided</U> that, such transfer shall not involve a disposition for value and each donee, devisee, transferee or distributee shall execute and deliver to the representatives a
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">
<FONT STYLE="white-space:nowrap">lock-up</FONT> letter in the form of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements, <U>provided further</U> that no public filing, report or
announcement shall be voluntarily made and if any filing under Section&nbsp;16(a) of the Exchange Act, or other public filing, report or announcement reporting a reduction in beneficial ownership of shares of common stock in connection with such
transfer or distribution shall be legally required during the restricted period, such filing, report or announcement shall clearly indicate in the footnotes thereto the nature and conditions of such transfer; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to us from an employee upon death, disability or termination of employment, in each case, of such employee, <U>provided</U> that no public filing, report or announcement shall be voluntarily made and if any filing under
Section&nbsp;16(a) of the Exchange Act, or other public filing, report or announcement reporting a reduction in beneficial ownership of shares of common stock in connection with such transfer or distribution shall be legally required during the
restricted period, such filing, report or announcement shall clearly indicate in the footnotes thereto the nature and conditions of such transfer; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">as part of a sale of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities acquired in this offering or in open market transactions after the closing date of this offering, <U>provided</U> that no filing by any
party (donor, donee, devisee, transferor, transferee, distributer or distributee) under the Exchange Act, or other public announcement shall be required or shall be made voluntarily in connection with such transfer or distribution (other than a
filing on a Form 5 made after the expiration of the restricted period); </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to us in connection with the vesting, settlement, or exercise of RSUs, options, warrants or other rights to purchase shares of common stock (including, in each case, by way of &#8220;net&#8221; or &#8220;cashless&#8221;
exercise), including for the payment of exercise price and tax and remittance payments due as a result of the vesting, settlement, or exercise of such RSUs, options, warrants or rights, <U>provided</U> that any such shares of common stock received
upon such exercise, vesting or settlement shall be subject to the terms of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, <U>provided further</U> that any such RSUs, options, warrants or rights are held by the <FONT
STYLE="white-space:nowrap">lock-up</FONT> party pursuant to an agreement or equity awards granted under a stock incentive plan or other equity award plan, each such agreement or plan which is described in this prospectus supplement, <U>provided
further</U> that no public filing, report or announcement reporting a reduction in beneficial ownership of shares of common stock shall be voluntarily made during the restricted period, and if the <FONT STYLE="white-space:nowrap">lock-up</FONT>
party is required to file a report reporting a reduction in beneficial ownership of shares of common stock during the restricted period, the <FONT STYLE="white-space:nowrap">lock-up</FONT> party shall clearly indicate in the footnotes thereto that
the filing relates to the circumstances described in this clause and that the shares of common stock received upon exercise of the stock option or warrant or RSU or other right or vesting event are subject to the
<FONT STYLE="white-space:nowrap">lock-up</FONT> agreement, and no public filing, report or announcement shall be voluntarily made; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">transfer or dispose shares of common stock or any security convertible into or exercisable or exchangeable for common stock to us pursuant to any contractual arrangement in effect on the date of the lock up agreement
and disclosed in this prospectus supplement that provides for the repurchase of shares of common stock in connection with the termination of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party&#8217;s employment with or service to us,
<U>provided</U> that no public filing, report or announcement reporting a reduction in beneficial ownership of shares of common stock shall be voluntarily made during the restricted period, and if the <FONT STYLE="white-space:nowrap">lock-up</FONT>
party is required to file a report reporting a reduction in beneficial ownership of shares of common stock during the restricted period, such report or filing shall clearly indicate in the footnotes thereto that the filing relates to the
circumstances described in this clause and no public filing, report or announcement shall be voluntarily made; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pursuant to a bona fide third-party tender offer, merger, consolidation or other similar transaction that is approved by our board of directors and made to all holders of our capital stock involving a change of control
(as defined in the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement) of us, <U>provided</U> that in the event that such tender offer, merger, consolidation or other similar transaction is not completed, the
<FONT STYLE="white-space:nowrap">lock-up</FONT> securities shall remain subject to the provisions of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement; </TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pursuant to a trading plan under Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act that is existing on the date of this prospectus supplement which has been provided to the underwriters or its
legal counsel; <U>provided</U> that (1)&nbsp;to the extent a public announcement or filing under the Exchange Act, if any, is required by or on behalf of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party or us regarding such transfer during
the restricted period, such announcement or filing shall include the date that the trading plan was entered into and a statement that such transfer is in accordance with an established trading plan, and (2)&nbsp;the existing trading plan may not be
amended during the restricted period to allow for an increase in the number of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities that may be sold pursuant to such existing trading plan; </TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">exercise outstanding options, settle RSUs or other equity awards or exercise warrants pursuant to plans described in this prospectus supplement; <U>provided</U> that any <FONT STYLE="white-space:nowrap">lock-up</FONT>
securities received upon such exercise, vesting or settlement shall be subject to the terms of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement; and </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the establishment by <FONT STYLE="white-space:nowrap">lock-up</FONT> parties of trading plans under Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> under the Exchange Act for the transfer of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> securities, <U>provided</U> that (1)&nbsp;such plan does not provide for the transfer of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities during the restricted period and (2)&nbsp;no filing by any
party under the Exchange Act or other public announcement shall be made voluntarily in connection with such trading plan during the restricted period and if any filing under Section&nbsp;16(a) of the Exchange Act, or other public filing, report or
announcement shall be legally required during the restricted period, such filing, report or announcement shall clearly indicate in the footnotes thereto and the nature and conditions of such establishment. </TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">J.P. Morgan Securities LLC, in its sole discretion, may release the securities subject to any of the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the
underwriters described above, in whole or in part at any time. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have agreed to indemnify the underwriters against certain liabilities, including liabilities under
the Securities Act. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#8220;ERAS.&#8221; </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with this offering, the underwriters may engage in stabilizing transactions, which involves making bids for, purchasing and selling shares of common stock
in the open market for the purpose of preventing or retarding a decline in the market price of the common stock while this offering is in progress. These stabilizing transactions may include making short sales of common stock, which involves the
sale by the underwriters of a greater number of shares of common stock than they are required to purchase in this offering, and purchasing shares of common stock on the open market to cover positions created by short sales. Short sales may be
&#8220;covered&#8221; shorts, which are short positions in an amount not greater than the underwriters&#8217; option to purchase additional shares referred to above, or may be &#8220;naked&#8221; shorts, which are short positions in excess of that
amount. The underwriters may close out any covered short position either by exercising their option to purchase additional shares, in whole or in part, or by purchasing shares in the open market. In making this determination, the underwriters will
consider, among other things, the price of shares available for purchase in the open market compared to the price at which the underwriters may purchase shares through the option to purchase additional shares. A naked short position is more likely
to be created if the underwriters are concerned that there may be downward pressure on the price of the common stock in the open market that could adversely affect investors who purchase in this offering. To the extent that the underwriters create a
naked short position, they will purchase shares in the open market to cover the position. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriters have advised us that, pursuant to Regulation&nbsp;M of the Securities Act, they may also engage in
other activities that stabilize, maintain or otherwise affect the price of the common stock, including the imposition of penalty bids. This means that if the representatives of the underwriters purchase common stock in the open market in stabilizing
transactions or to cover short sales, the representatives can require the underwriters that sold those shares as part of this offering to repay the underwriting discount received by them. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These activities may have the effect of raising or maintaining the market price of the common stock or preventing or retarding a decline in the market price of the
common stock, and, as a result, the price of the common stock may be higher than the price that otherwise might exist in the open market. If the underwriters commence these activities, they may discontinue them at any time. The underwriters may
carry out these transactions on the Nasdaq Global Select Market, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Other relationships </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Certain of the underwriters and their affiliates have
provided in the past to us and our affiliates and may provide from time to time in the future certain commercial banking, financial advisory, investment banking and other services for us and such affiliates in the ordinary course of their business,
for which they have received and may continue to receive customary fees and commissions. For example, we entered into the Sales Agreement with Jefferies LLC as the sales agent, as amended from time to time, and pursuant to which we may offer and
sell shares of our common stock through Jefferies LLC in an &#8220;at the market offering&#8221; as defined in Rule 415(a)(4) promulgated under the Securities Act. In addition, from time to time, certain of the underwriters and their affiliates may
effect transactions for their own account or the account of customers, and hold on behalf of themselves or their customers, long or short positions in our debt or equity securities or loans, and may do so in the future. For example, certain of the
underwriters also served as underwriters in our 2024 public offering. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Selling restrictions </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Other than in the United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered by this prospectus
supplement and the accompanying prospectus in any jurisdiction where action for that purpose is required. The securities offered by this prospectus supplement and the accompanying prospectus may not be offered or sold, directly or indirectly, nor
may this prospectus supplement and the accompanying prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction, except under circumstances
that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus supplement and the accompanying prospectus comes are advised to inform themselves about and to observe any
restrictions relating to this offering and the distribution of this prospectus supplement and the accompanying prospectus. This prospectus supplement and the accompanying prospectus do not constitute an offer to sell or a solicitation of an offer to
buy any securities offered by this prospectus supplement and the accompanying prospectus in any jurisdiction in which such an offer or a solicitation is unlawful. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Notice to prospective investors in the European Economic Area </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In
relation to each Member State of the European Economic Area, each a Relevant State, no shares of common stock have been offered or will be offered pursuant to this offering to the public in that Relevant State prior to the publication of a
prospectus in relation to the shares of common stock which has been approved by the competent authority in that Relevant State or, where appropriate, approved in another Relevant State and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation, except that offers of shares of common stock may be made to the public in that
Relevant State at any time under the following exemptions under the Prospectus Regulation: </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">(a) to any legal entity which is a qualified investor as defined under
Article 2 of the Prospectus Regulation; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">(b) to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the Prospectus
Regulation), subject to obtaining the prior consent of the underwriters; or </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">(c) in any other circumstances falling within Article 1(4) of the Prospectus Regulation,
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">provided that no such offer of shares of common stock shall require us or any underwriter to publish a prospectus pursuant to Article 3 of the Prospectus Regulation
or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. and each person who initially acquires any shares of common stock or to whom any offer is made will be deemed to have represented, acknowledged and agreed to and with
each of the underwriters and us that it is a &#8220;qualified investor&#8221; within the meaning of Article 2(e) of the Prospectus Regulation. In the case of any shares of common stock being offered to a financial intermediary as that term is used
in the Prospectus Regulation, each such financial intermediary will be deemed to have represented, acknowledged and agreed that the shares of common stock acquired by it in the offer have not been acquired on a
<FONT STYLE="white-space:nowrap">non-discretionary</FONT> basis on behalf of, nor have they been acquired with a view to their offer or resale to, persons in circumstances which may give rise to an offer of any shares of common stock to the public
other than their offer or resale in a Relevant State to qualified investors as so defined or in circumstances in which the prior consent of the underwriters have been obtained to each such proposed offer or resale. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For the purposes of this provision, the expression an &#8220;offer to the public&#8221; in relation to shares of common stock in any Relevant State means the
communication in any form and by any means of sufficient information on the terms of the offer and any shares of common stock to be offered so as to enable an investor to decide to purchase or subscribe for any shares of common stock, and the
expression &#8220;Prospectus Regulation&#8221; means Regulation (EU) 2017/1129. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Notice to prospective investors in the United Kingdom </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">No shares of our common stock have been offered or will be offered pursuant to this offering to the public in the United Kingdom prior to the publication of a prospectus
in relation to the shares of our common stock which has been approved by the Financial Conduct Authority, except that the shares of our common stock may be offered to the public in the United Kingdom at any time: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to any legal entity which is a qualified investor as defined under Article 2 of the UK Prospectus Regulation; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the UK Prospectus Regulation), subject to obtaining the prior consent of the representatives for any such offer;
or </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in any other circumstances falling within Section&nbsp;86 of the FSMA. </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">provided that no such offer of the shares of our
common stock shall require us or any underwriter to publish a prospectus pursuant to Section&nbsp;85 of the FSMA or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation. For the purposes of this provision, the expression an
&#8220;offer to the public&#8221; in relation to the shares of our common stock in the United Kingdom means the communication in any form and by any means of sufficient information on the terms of the offer and any shares of our common stock to be
offered so </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
as to enable an investor to decide to purchase or subscribe for any shares of our common stock and the expression &#8220;UK Prospectus Regulation&#8221; means Regulation (EU) 2017/1129 as it
forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, in the United Kingdom, this document is being distributed only to,
and is directed only at, and any offer subsequently made may only be directed at persons who are &#8220;qualified investors&#8221; (as defined in the Prospectus Regulation)&nbsp;(i) who have professional experience in matters relating to investments
falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended, or the Order, and/or (ii)&nbsp;who are high net worth companies (or persons to whom it may otherwise be lawfully communicated)
falling within Article 49(2)(a) to (d)&nbsp;of the Order, or, all such persons together being referred to as relevant persons, or otherwise in circumstances which have not resulted and will not result in an offer to the public of the securities in
the United Kingdom within the meaning of the Financial Services and Markets Act 2000. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any person in the United Kingdom that is not a relevant person should not act
or rely on the information included in this document or use it as basis for taking any action. In the United Kingdom, any investment or investment activity that this document relates to may be made or taken exclusively by relevant persons. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Notice to prospective investors in Canada </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares of our common
stock may be sold only to purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National <FONT STYLE="white-space:nowrap">Instrument&nbsp;45-106&nbsp;Prospectus</FONT> Exemptions or subsection
73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National <FONT STYLE="white-space:nowrap">Instrument&nbsp;31-103&nbsp;Registration</FONT> Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of
the shares of our common stock must be made in accordance with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus supplement
(including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#8217;s province or
territory. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser&#8217;s province or territory for particulars of these rights or consult with a legal advisor. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pursuant to section 3A.3 of National <FONT STYLE="white-space:nowrap">Instrument&nbsp;33-105&nbsp;Underwriting</FONT> Conflicts
<FONT STYLE="white-space:nowrap">(NI&nbsp;33-105),&nbsp;the</FONT> underwriters are not required to comply with the disclosure requirements of <FONT STYLE="white-space:nowrap">NI&nbsp;33-105&nbsp;regarding</FONT> underwriter conflicts of interest in
connection with this offering. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Notice to prospective investors in Switzerland </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This prospectus supplement does not constitute an offer to the public or a solicitation to purchase or invest in any shares of our common stock. No shares of our common
stock have been offered or will be offered to the public in Switzerland, except that offers of shares of our common stock may be made to the public in Switzerland at any time under the following exemptions under the Swiss Financial Services Act, or
FinSA: </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">(a) to any person which is a professional client as defined under the FinSA; </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">(b) to fewer than 500 persons (other than professional clients as defined under the FinSA), subject to obtaining the prior consent of the representatives of the
underwriters any such offer; or </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">(c) in any other circumstances falling within Article 36 FinSA in connection with Article 44 of the Swiss Financial Services
Ordinance, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>provided that</I> no such offer of shares of our common stock shall require us or any investment bank to publish a
prospectus pursuant to Article 35 FinSA. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares of our common stock have not been and will not be listed or admitted to trading on a trading venue in
Switzerland. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Neither this prospectus supplement nor any other offering or marketing material relating to the shares of our common stock constitutes a prospectus as
such term is understood pursuant to the FinSA and neither this prospectus supplement nor any other offering or marketing material relating to the shares of our common stock may be publicly distributed or otherwise made publicly available in
Switzerland. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Notice to prospective investors in the Dubai International Financial Centre </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This prospectus supplement relates to an Exempt Offer in accordance with the Markets Law, DIFC Law No.&nbsp;1 of 2012, as amended. This prospectus supplement is intended
for distribution only to persons of a type specified in the Markets Law, DIFC Law No.&nbsp;1 of 2012, as amended. It must not be delivered to, or relied on by, any other person. The Dubai Financial Services Authority, or the DFSA, has no
responsibility for reviewing or verifying any documents in connection with Exempt Offers. The DFSA has not approved this prospectus supplement nor taken steps to verify the information set forth herein and has no responsibility for this prospectus
supplement. The securities to which this prospectus supplement relates may be illiquid and/or subject to restrictions on their resale. Prospective purchasers of the securities offered should conduct their own due diligence on the securities. If you
do not understand the contents of this prospectus supplement you should consult an authorized financial advisor. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In relation to its use in the DIFC, this prospectus
supplement is strictly private and confidential and is being distributed to a limited number of investors and must not be provided to any person other than the original recipient, and may not be reproduced or used for any other purpose. The
interests in the securities may not be offered or sold directly or indirectly to the public in the DIFC. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Notice to prospective investors in the United Arab
Emirates </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares have not been, and are not being, publicly offered, sold, promoted or advertised in the United Arab Emirates (including the Dubai
International Financial Centre) other than in compliance with the laws of the United Arab Emirates (and the Dubai International Financial Centre) governing the issue, offering and sale of securities. Further, this prospectus supplement does not
constitute a public offer of securities in the United Arab Emirates (including the Dubai International Financial Centre) and is not intended to be a public offer. This prospectus supplement has not been approved by or filed with the Central Bank of
the United Arab Emirates, the Securities and Commodities Authority, Financial Services Regulatory Authority or the DFSA. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Notice to prospective investors in
Australia </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This prospectus supplement: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">does not constitute a disclosure document or a prospectus under Chapter 6D.2 of the Corporations Act 2001 (Cth), or the
Corporations Act; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">has not been, and will not be, lodged with the Australian Securities and Investments Commission, or the ASIC, as a
disclosure document for the purposes of the Corporations Act and does not purport to include the information required of a disclosure document for the purposes of the Corporations Act; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">may only be provided in Australia to select investors who are able to demonstrate that they fall within one or more of the
categories of investors, available under section 708 of the Corporations Act, or the Exempt Investors. </P></TD></TR></TABLE> <P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares of our common stock may not be directly or indirectly offered for subscription or purchased or sold, and no
invitations to subscribe for or buy the shares of our common stock may be issued, and no draft or definitive offering memorandum, advertisement or other offering material relating to any shares of our common stock may be distributed in Australia,
except where disclosure to investors is not required under Chapter 6D of the Corporations Act or is otherwise in compliance with all applicable Australian laws and regulations. By submitting an application for the shares of our common stock, you
represent and warrant to us that you are an Exempt Investor. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As any offer of shares of our common stock under this prospectus supplement will be made without
disclosure in Australia under Chapter 6D.2 of the Corporations Act, the offer of those securities for resale in Australia within 12 months may, under section 707 of the Corporations Act, require disclosure to investors under Chapter 6D.2 if none of
the exemptions in section 708 applies to that resale. By applying for the shares of our common stock you undertake to us that you will not, for a period of 12 months from the date of issue of the shares, offer, transfer, assign or otherwise alienate
those shares of our common stock to investors in Australia except in circumstances where disclosure to investors is not required under Chapter 6D.2 of the Corporations Act or where a compliant disclosure document is prepared and lodged with ASIC.
</P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Notice to prospective investors in Japan </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares of our
common stock have not been and will not be registered pursuant to Article 4, Paragraph 1 of the Financial Instruments and Exchange Act. Accordingly, none of the shares of our common stock nor any interest therein may be offered or sold, directly or
indirectly, in Japan or to, or for the benefit of, any &#8220;resident&#8221; of Japan (which term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others <FONT
STYLE="white-space:nowrap">for&nbsp;re-offering&nbsp;or</FONT> resale, directly or indirectly, in Japan or to or for the benefit of a resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in
compliance with, the Financial Instruments and Exchange Act and any other applicable laws, regulations and ministerial guidelines of Japan in effect at the relevant time. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Notice to prospective investors in Hong Kong </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares of our common
stock have not been offered or sold and will not be offered or sold in Hong Kong, by means of any document, other than (a)&nbsp;to &#8220;professional investors&#8221; as defined in the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong
Kong), or the SFO, of Hong Kong and any rules made thereunder; or (b)&nbsp;in other circumstances which do not result in the document being a &#8220;prospectus&#8221; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance
(Cap. 32) of Hong Kong, or the CO, or which do not constitute an offer to the public within the meaning of the CO. No advertisement, invitation or document relating to the shares of our common stock has been or may be issued or has been or may be in
the possession of any person for the purposes of issue, whether in Hong Kong or elsewhere, which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted to do so under the
securities laws of Hong Kong) other than with respect to the shares of our common stock which are or are intended to be disposed of only to persons outside Hong Kong or only to &#8220;professional investors&#8221; as defined in the SFO and any rules
made thereunder. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Notice to prospective investors in Singapore </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This prospectus supplement has not been registered as a prospectus with the Monetary Authority of Singapore. Accordingly, no shares of common stock have been or will be
offered or sold and no shares of common stock have been or will be made the subject of an invitation for subscription or purchase, and no prospectus </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
supplement or any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares of common stock, has been or will be circulated or
distributed, whether directly or indirectly, to any person in Singapore other than: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to an institutional investor (as defined in Section&nbsp;4A of the Securities and Futures Act (Chapter 289) of Singapore, as modified or amended from time to time, or the SFA) pursuant to Section&nbsp;274 of the SFA;
</TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to a relevant person (as defined in Section&nbsp;275(2) of the SFA) pursuant to Section&nbsp;275(1) of the SFA, or any person pursuant to Section&nbsp;275(1A) of the SFA, and in accordance with the conditions specified
in Section&nbsp;275 of the SFA; or </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Singapore
SFA Product Classification&#8212;</I>In connection with Section&nbsp;309B of the SFA and the CMP Regulations 2018, unless otherwise specified before an offer of Notes, the Issuer has determined, and hereby notifies all relevant persons (as defined
in Section&nbsp;309A(1) of the SFA), that the Notes are &#8216;&#8216;prescribed capital markets products&#8217;&#8217; (as defined in the CMP Regulations 2018) and Excluded Investment Products (as defined in MAS Notice SFA <FONT
STYLE="white-space:nowrap">04-N12:</FONT> Notice on the Sale of Investment Products and MAS Notice <FONT STYLE="white-space:nowrap">FAA-N16:</FONT> Notice on Recommendations on Investment Products). </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Notice to prospective investors in Bermuda </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Shares of our common stock
may be offered or sold in Bermuda only in compliance with the provisions of the Investment Business Act of 2003 of Bermuda which regulates the sale of securities in Bermuda. Additionally, <FONT STYLE="white-space:nowrap">non-Bermudian</FONT> persons
(including companies) may not carry on or engage in any trade or business in Bermuda unless such persons are permitted to do so under applicable Bermuda legislation. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Notice to prospective investors in Saudi Arabia </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This prospectus
supplement may not be distributed in the Kingdom of Saudi Arabia except to such persons as are permitted under the Rules on the Offer of Securities Regulations as issued by the board of the Saudi Arabian Capital Market Authority, or the CMA,
pursuant to resolution number <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">3-123-2017</FONT></FONT> dated December&nbsp;27, 2017, as amended. The CMA does not make any representation as to the accuracy or completeness of this
prospectus supplement and expressly disclaims any liability whatsoever for any loss arising from, or incurred in reliance upon, any part of this prospectus supplement. Prospective purchasers of the securities offered hereby should conduct their own
due diligence on the accuracy of the information relating to the securities. If you do not understand the contents of this prospectus supplement, you should consult an authorized financial adviser. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Notice to prospective investors in the British Virgin Islands </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
shares are not being, and may not be offered to the public or to any person in the British Virgin Islands for purchase or subscription by or on behalf of our company. The shares of our common stock may be offered to companies incorporated under the
BVI Business Companies Act, 2004 (British Virgin Islands), or BVI Companies, but only where the offer will be made to, and received by, the relevant BVI Company entirely outside of the British Virgin Islands. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Notice to prospective investors in China </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This prospectus supplement
will not be circulated or distributed in the PRC and the shares of our common stock will not be offered or sold, and will not be offered or sold to any person for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale directly or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
indirectly to any residents of the PRC (for such purposes, not including the Hong Kong and Macau Special Administrative Regions or Taiwan) except pursuant to any applicable laws and regulations
of the PRC. Neither this prospectus supplement nor any advertisement or other offering material may be distributed or published in the PRC, except under circumstances that will result in compliance with applicable laws and regulations. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Notice to prospective investors in Korea </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares have not been and
will not be registered under the Financial Investments Services and Capital Markets Act of Korea and the decrees and regulations thereunder, or the FSCMA, and the shares have been and will be offered in Korea as a private placement under the FSCMA.
None of the shares may be offered, sold or delivered directly or indirectly, or offered or sold to any person for <FONT STYLE="white-space:nowrap">re-offering</FONT> or resale, directly or indirectly, in Korea or to any resident of Korea except
pursuant to the applicable laws and regulations of Korea, including the FSCMA and the Foreign Exchange Transaction Law of Korea and the decrees and regulations thereunder, or FETL. The shares have not been listed on any of securities exchanges in
the world including, without limitation, the Korea Exchange in Korea. Furthermore, the purchaser of the shares of our common stock shall comply with all applicable regulatory requirements (including but not limited to requirements under the FETL) in
connection with the purchase of the shares. By the purchase of the shares, the relevant holder thereof will be deemed to represent and warrant that if it is in Korea or is a resident of Korea, it purchased the shares pursuant to the applicable laws
and regulations of Korea. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Notice to prospective investors in Malaysia </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">No prospectus or other offering material or document in connection with the offer and sale of the shares has been or will be registered with the Securities Commission of
Malaysia, or the Malaysian Commission, for the Malaysian Commission&#8217;s approval pursuant to the Capital Markets and Services Act 2007. Accordingly, this prospectus supplement and any other document or material in connection with the offer or
sale, or invitation for subscription or purchase, of the shares may not be circulated or distributed, nor may the shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to
persons in Malaysia other than (i)&nbsp;a closed end fund approved by the Malaysian Commission; (ii)&nbsp;a holder of a Capital Markets Services License; (iii)&nbsp;a person who acquires the shares, as principal, if the offer is on terms that the
shares may only be acquired at a consideration of not less than RM250,000 (or its equivalent in foreign currencies) for each transaction; (iv)&nbsp;an individual whose total net personal assets or total net joint assets with his or her spouse
exceeds RM3&nbsp;million (or its equivalent in foreign currencies), excluding the value of the primary residence of the individual; (v)&nbsp;an individual who has a gross annual income exceeding RM300,000 (or its equivalent in foreign currencies)
per annum in the preceding twelve months; (vi)&nbsp;an individual who, jointly with his or her spouse, has a gross annual income of RM400,000 (or its equivalent in foreign currencies), per annum in the preceding twelve months; (vii)&nbsp;a
corporation with total net assets exceeding RM10&nbsp;million (or its equivalent in a foreign currencies) based on the last audited accounts; (viii)&nbsp;a partnership with total net assets exceeding RM10&nbsp;million (or its equivalent in foreign
currencies); (ix) a bank licensee or insurance licensee as defined in the Labuan Financial Services and Securities Act 2010; (x) an Islamic bank licensee or takaful licensee as defined in the Labuan Financial Services and Securities Act 2010; and
(xi)&nbsp;any other person as may be specified by the Malaysian Commission; provided that, in the each of the preceding categories (i)&nbsp;to (xi), the distribution of the shares is made by a holder of a Capital Markets Services License who carries
on the business of dealing in securities. The distribution in Malaysia of this prospectus supplement is subject to Malaysian laws. This prospectus supplement does not constitute and may not be used for the purpose of public offering or an issue,
offer for subscription or purchase, invitation to subscribe for or purchase any securities requiring the registration of a prospectus with the Malaysian Commission under the Capital Markets and Services Act 2007. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Notice to prospective investors in Taiwan </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The shares have not been and will not be registered with the Financial Supervisory Commission of Taiwan pursuant to relevant securities laws and regulations and may not
be sold, issued or offered within Taiwan through a public offering or in circumstances which constitutes an offer within the meaning of the Securities and Exchange Act of Taiwan that requires a registration or approval of the Financial Supervisory
Commission of Taiwan. No person or entity in Taiwan has been authorized to offer, sell, give advice regarding or otherwise intermediate the offering and sale of the shares in Taiwan. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Notice to prospective investors in South Africa </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Due to restrictions
under the securities laws of South Africa, no &#8220;<I>offer to the public</I>&#8221; (as such term is defined in the South African Companies Act, No.&nbsp;71 of 2008 (as amended or <FONT STYLE="white-space:nowrap">re-enacted),</FONT> or the South
African Companies Act, is being made in connection with the issue of the shares in South Africa. Accordingly, this prospectus supplement does not, nor is it intended to, constitute a &#8220;<I>registered prospectus</I>&#8221; (as that term is
defined in the South African Companies Act) prepared and registered under the South African Companies Act and has not been approved by, and/or filed with, the South African Companies and Intellectual Property Commission or any other regulatory
authority in South Africa. The shares are not offered, and the offer shall not be transferred, sold, renounced or delivered, in South Africa or to a person with an address in South Africa, unless one or other of the following exemptions stipulated
in section 96 (1) applies: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="20%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial">Section&nbsp;96 (1) (a) </P></TD>
<TD>the offer, transfer, sale, renunciation or delivery is to: </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons whose ordinary business, or part of whose ordinary business, is to deal in securities, as principal or agent; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the South African Public Investment Corporation; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">persons or entities regulated by the Reserve Bank of South Africa; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">authorised financial service providers under South African law; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">financial institutions recognised as such under South African law; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vi)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a wholly-owned subsidiary of any person or entity contemplated in (c), (d) or (e), acting as agent in the capacity of an authorized portfolio manager for a pension fund, or as manager for a collective investment scheme
(in each case duly registered as such under South African law); or </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="20%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(vii)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any combination of the person in (i)&nbsp;to (vi); or </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="20%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial">Section&nbsp;96 (1) (b) </P></TD>
<TD>the total contemplated acquisition cost of the securities, for any single addressee acting as principal is equal to or greater than ZAR1,000,000 or such higher amount as may be promulgated by notice in the Government Gazette of South Africa
pursuant to section 96(2)(a) of the South African Companies Act. </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Information made available in this prospectus supplement should not be considered as
&#8220;advice&#8221; as defined in the South African Financial Advisory and Intermediary Services Act, 2002. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Notice to prospective investors in Israel
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the State of Israel this prospectus supplement shall not be regarded as an offer to the public to purchase shares of common stock under the Israeli
Securities Law, 5728&#8212;1968, which requires a prospectus to be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
published and authorized by the Israel Securities Authority, if it complies with certain provisions of Section&nbsp;15 of the Israeli Securities Law, 5728&#8211;1968, including, inter alia, if:
(i)&nbsp;the offer is made, distributed or directed to not more than 35 investors, subject to certain conditions, or the Addressed Investors; or (ii)&nbsp;the offer is made, distributed or directed to certain qualified investors defined in the First
Addendum of the Israeli Securities Law, 5728&#8212;1968, subject to certain conditions, or the Qualified Investors. The Qualified Investors shall not be taken into account in the count of the Addressed Investors and may be offered to purchase
securities in addition to the 35 Addressed Investors. We have not and will not take any action that would require us to publish a prospectus in accordance with and subject to the Israeli Securities Law, 5728&#8212;1968. We have not and will not
distribute this prospectus supplement or make, distribute or direct an offer to subscribe for our shares of common stock to any person within the State of Israel, other than to Qualified Investors and up to 35 Addressed Investors. Qualified
Investors may have to submit written evidence that they meet the definitions set out in of the First Addendum to the Israeli Securities Law, 5728&#8212;1968. In particular, we may request, as a condition to be offered shares of common stock, that
Qualified Investors will each represent, warrant and certify to us and/or to anyone acting on our behalf: (i)&nbsp;that it is an investor falling within one of the categories listed in the First Addendum to the Israeli Securities Law,
5728&#8212;1968; (ii) which of the categories listed in the First Addendum to the Israeli Securities Law, 5728&#8212;1968 regarding Qualified Investors is applicable to it; (iii)&nbsp;that it will abide by all provisions set forth in the Israeli
Securities Law, 5728&#8212;1968 and the regulations promulgated thereunder in connection with the offer to be issued shares of common stock; (iv)&nbsp;that the shares of common stock that it will be issued are, subject to exemptions available under
the Israeli Securities Law, 5728&#8212;1968: (a) for its own account; (b)&nbsp;for investment purposes only; and (c)&nbsp;not issued with a view to resale within the State of Israel, other than in accordance with the provisions of the Israeli
Securities Law, 5728&#8212;1968; and (v)&nbsp;that it is willing to provide further evidence of its Qualified Investor status. Addressed Investors may have to submit written evidence in respect of their identity and may have to sign and submit a
declaration containing, inter alia, the Addressed Investor&#8217;s name, address and passport number or Israeli identification number. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="supptoc63320_8"></A>Legal matters </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Latham&nbsp;&amp; Watkins LLP, San Diego, California, will pass upon certain legal matters relating to the issuance and sale of the securities offered hereby on behalf
of Erasca, Inc. Latham&nbsp;&amp; Watkins LLP and certain attorneys in the firm who have rendered, and will continue to render, legal services to us, own shares of our common stock representing in the aggregate less than one percent of the shares of
our common stock outstanding. The underwriters are being represented in connection with this offering by Cooley LLP, San Diego, California. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="supptoc63320_9"></A>Experts </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The consolidated financial statements of Erasca, Inc. as of December&nbsp;31, 2024 and 2023, and for the years then ended, have been incorporated by
reference herein and in the registration statement in reliance upon the report of KPMG LLP, independent registered public accounting firm, incorporated by reference herein, and upon the authority of said firm as experts in accounting and auditing.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="supptoc63320_10"></A>Where you can find more information; incorporation by reference </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Available information </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have filed with the SEC a registration statement on
Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act, of which this prospectus supplement forms a part. The rules and regulations of the SEC allow us to omit from this prospectus supplement and the accompanying prospectus
certain information included in the registration statement. For further information about us and the securities we are offering under this prospectus supplement, you should refer to the registration statement and the exhibits and schedules filed
with the registration statement. With respect to the statements contained in this prospectus supplement and the accompanying prospectus regarding the contents of any agreement or any other document, in each instance, the statement is qualified in
all respects by the complete text of the agreement or document, a copy of which has been filed as an exhibit to the registration statement. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We file reports, proxy
statements and other information with the SEC. The SEC maintains a website that contains reports, proxy and information statements and other information about issuers, such as us, who file electronically with the SEC. The address of that website is
http://www.sec.gov. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our website address is www.erasca.com. The information on, or accessible through, our website is not part of, and is not incorporated into, this
prospectus supplement or the accompanying prospectus and should not be considered part of this prospectus supplement or the accompanying prospectus. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Incorporation by reference </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The SEC&#8217;s rules allow us to
&#8220;incorporate by reference&#8221; information into this prospectus supplement, which means that we can disclose important information to you by referring you to another document filed separately with the SEC. The information incorporated by
reference is deemed to be part of this prospectus supplement and the accompanying prospectus, and subsequent information that we file with the SEC will automatically update and supersede that information. Any statement contained in this prospectus
supplement or a previously filed document incorporated by reference will be deemed to be modified or superseded for purposes of this prospectus supplement and the accompanying prospectus to the extent that a statement contained in this prospectus
supplement, the accompanying prospectus, or a subsequently filed document incorporated by reference modifies or replaces that statement. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This prospectus supplement
and the accompanying prospectus incorporate by reference the documents set forth below that have previously been filed with the SEC: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1761918/000095017025042682/eras-20241231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the year ended December&nbsp;31, 2024, filed with the SEC on March&nbsp;20, 2025; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the information specifically incorporated by reference into our Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K</FONT> from our Definitive Proxy Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1761918/000119312525103868/d897507ddef14a.htm">Schedule&nbsp;14A</A>, filed with
the SEC on April&nbsp;29, 2025; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarters ended March&nbsp;31, 2025,
June&nbsp;30, 2025 and September&nbsp;30, 2025, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1761918/000095017025070418/eras-20250331.htm">May&nbsp;
13, 2025</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1761918/000119312525178996/eras-20250630.htm">August&nbsp;
12, 2025</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1761918/000119312525277625/eras-20250930.htm">November&nbsp;12, 2025</A>, respectively; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1761918/000095017025090493/eras-20250624.htm">June&nbsp;26,
 2025</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1761918/000119312526009820/eras-20260112.htm">January&nbsp;12, 2026</A> (in each case, to the extent information therein is filed and not furnished);
and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the description of our common stock contained in the registration statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1761918/000119312521214084/d203245d8a12b.htm">Form
 <FONT STYLE="white-space:nowrap">8-A</FONT></A>, filed with the SEC on July&nbsp;13, 2021, and any amendment or report filed with the SEC for the purpose of updating the description. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">All reports and other documents we subsequently file pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the
Exchange Act prior to the termination of this offering, excluding any information furnished to, rather than filed with, the SEC, will also be incorporated by reference into this prospectus supplement and the accompanying prospectus and deemed to be
part of this prospectus supplement and the accompanying prospectus from the date of the filing of such reports and documents. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">You may request a free copy of any of
the documents incorporated by reference in this prospectus supplement and the accompanying prospectus (other than exhibits, unless they are specifically incorporated by reference in the documents) by writing or telephoning us at the following
address: </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">Erasca, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">Attention: Corporate
Secretary </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">3115 Merryfield Row, Suite 300 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">San
Diego, California 92121 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">(858) <FONT STYLE="white-space:nowrap">465-6511</FONT> </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Exhibits to the filings will not be sent, however, unless those exhibits have specifically been incorporated by reference in this prospectus supplement or the
accompanying prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">S-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g63320g08k04.jpg" ALT="LOGO" STYLE="width:2.54667in;height:0.43in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>$500,000,000 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Preferred
Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Debt Securities </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Units </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may offer and sell up to $500,000,000 in the aggregate of the securities identified above from time to time in one or more offerings. This prospectus
provides you with a general description of the securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each time we offer and sell securities, we will provide a supplement to this prospectus that
contains specific information about the offering and the amounts, prices and terms of the securities. The supplement may also add, update or change information contained in this prospectus with respect to that offering. You should carefully read
this prospectus and the applicable prospectus supplement, together with the documents we incorporate by reference, before you invest in any of our securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may offer and sell the securities described in this prospectus and any prospectus supplement to or through one or more underwriters, dealers and agents, or
directly to purchasers, or through a combination of these methods. If any underwriters, dealers or agents are involved in the sale of any of the securities, their names and any applicable purchase price, fee, commission or discount arrangement
between or among them will be set forth, or will be calculable from the information set forth, in the applicable prospectus supplement. See the sections of this prospectus entitled &#8220;About this Prospectus&#8221; and &#8220;Plan of
Distribution&#8221; for more information. No securities may be sold without delivery of this prospectus and the applicable prospectus supplement describing the method and terms of the offering of such securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>INVESTING IN OUR SECURITIES INVOLVES RISKS. SEE THE &#8220;<A HREF="#tx63320_4">RISK FACTORS</A>&#8221; ON PAGE 5 OF THIS PROSPECTUS AND ANY SIMILAR
SECTION CONTAINED IN THE APPLICABLE PROSPECTUS SUPPLEMENT CONCERNING FACTORS YOU SHOULD CONSIDER BEFORE INVESTING IN OUR SECURITIES. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock
is listed on the Nasdaq Global Select Market under the symbol &#8220;ERAS.&#8221; On August&nbsp;8, 2025, the last reported sale price of our common stock on the Nasdaq Global Select Market was $1.40 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the
adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is August&nbsp;22, 2025. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx63320_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx63320_2">WHERE YOU CAN FIND MORE INFORMATION; INCORPORATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx63320_3">THE COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx63320_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx63320_5">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx63320_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx63320_7">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx63320_8">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx63320_9">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx63320_10">DESCRIPTION OF UNITS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx63320_11">GLOBAL SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx63320_12">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx63320_13">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#tx63320_14">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx63320_1"></A><A NAME="supptoc63320_11"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement that we filed with the U.S. Securities and Exchange Commission (the SEC) using a &#8220;shelf&#8221;
registration process. By using a shelf registration statement, we may sell securities from time to time and in one or more offerings, up to a total dollar amount of $500&nbsp;million as described in this prospectus. Each time that we offer and sell
securities, we will provide a prospectus supplement to this prospectus that contains specific information about the securities being offered and sold and the specific terms of that offering. We may also authorize one or more free writing
prospectuses to be provided to you that may contain material information relating to these offerings. The prospectus supplement or free writing prospectus may also add, update or change information contained in this prospectus with respect to that
offering. If there is any inconsistency between the information in this prospectus and the applicable prospectus supplement or free writing prospectus, you should rely on the prospectus supplement or free writing prospectus, as applicable. Before
purchasing any securities, you should carefully read both this prospectus and the applicable prospectus supplement (and any applicable free writing prospectuses), together with the additional information described under the heading &#8220;Where You
Can Find More Information; Incorporation by Reference.&#8221; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not authorized anyone to provide you with any information or to make any
representations other than those contained in this prospectus, any applicable prospectus supplement or any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We take no responsibility for, and can provide no
assurance as to the reliability of, any other information that others may give you. We will not make an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in
this prospectus and the applicable prospectus supplement to this prospectus is accurate only as of the date on its respective cover, that the information appearing in any applicable free writing prospectus is accurate only as of the date of that
free writing prospectus, and that any information incorporated by reference is accurate only as of the date of the document incorporated by reference, unless we indicate otherwise. Our business, financial condition, results of operations and
prospects may have changed since those dates. This prospectus incorporates by reference, and any prospectus supplement or free writing prospectus may contain and incorporate by reference, market data and industry statistics and forecasts that are
based on independent industry publications and other publicly available information. Although we believe these sources are reliable, we do not guarantee the accuracy or completeness of this information and we have not independently verified this
information. In addition, the market and industry data and forecasts that may be included or incorporated by reference in this prospectus, any prospectus supplements or any applicable free writing prospectus, may involve estimates, assumptions, and
other risks and uncertainties and are subject to change based on various factors, including those discussed under the heading &#8220;Risk Factors&#8221; contained in this prospectus, the applicable prospectus supplement and any applicable free
writing prospectus, and under similar headings in other documents that are incorporated by reference into this prospectus. Accordingly, investors should not place undue reliance on this information. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">When we refer to &#8220;Erasca,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; &#8220;us&#8221; and the &#8220;Company&#8221; in this prospectus, we mean Erasca,
Inc. and its subsidiaries, unless otherwise specified. When we refer to &#8220;you,&#8221; we mean the potential holders of the applicable series of securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We use our trademarks in this prospectus as well as trademarks, tradenames and service marks that are the property of other organizations. Solely for
convenience, trademarks and tradenames referred to in this prospectus appear without the <SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and <SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> symbols, but those references are not
intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or that the applicable owner will not assert its rights, to these trademarks and tradenames. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx63320_2"></A><A NAME="supptoc63320_12"></A>WHERE YOU CAN FIND MORE INFORMATION;
INCORPORATION BY REFERENCE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Available Information </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We file reports, proxy statements and other information with the SEC. The SEC maintains a website that contains reports, proxy and information statements and
other information about issuers, including us, who file electronically with the SEC. The address of that website is http://www.sec.gov. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our website
address is www.erasca.com. The information on, or accessible through, our website, however, is not, and should not be deemed to be, a part of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus and any prospectus supplement are part of a registration statement that we filed with the SEC and do not contain all of the information in the
registration statement. The full registration statement may be obtained from the SEC or us, as provided below. Forms of the indenture and other documents establishing the terms of the offered securities are or may be filed as exhibits to the
registration statement or documents incorporated by reference in the registration statement. Statements in this prospectus or any prospectus supplement about these documents are summaries and each statement is qualified in all respects by reference
to the document to which it refers. You should refer to the actual documents for a more complete description of the relevant matters. You may inspect a copy of the registration statement through the SEC&#8217;s website, as provided above. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Incorporation by Reference </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC&#8217;s rules allow
us to &#8220;incorporate by reference&#8221; information into this prospectus, which means that we can disclose important information to you by referring you to another document filed separately with the SEC. The information incorporated by
reference is deemed to be part of this prospectus, and subsequent information that we file with the SEC will automatically update and supersede that information. Any statement contained in this prospectus or a previously filed document incorporated
by reference will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus or a subsequently filed document incorporated by reference modifies or replaces that statement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus and any accompanying prospectus supplement incorporate by reference the documents set forth below that have previously been filed with the
SEC: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2024,
filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1761918/000095017025042682/eras-20241231.htm">March&nbsp;20, 2025</A>; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the information specifically incorporated by reference into our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> from our Definitive Proxy Statement on Schedule 14A, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1761918/000119312525103868/d897507ddef14a.htm">April&nbsp;29,
 2025</A>; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarters ended March&nbsp;31,
2025 and June&nbsp;30, 2025, filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1761918/000095017025070418/eras-20250331.htm">May&nbsp;
13, 2025</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1761918/000119312525178996/eras-20250630.htm">August&nbsp;12, 2025</A>, respectively; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1761918/000095017025090493/eras-20250624.htm">June&nbsp;26,
 2025</A>; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock contained in our registration statement on Form <FONT
STYLE="white-space:nowrap">8-A,</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/0001761918/000119312521214084/d203245d8a12b.htm">July<U></U>&nbsp;13, 2021</A>, and any amendment or report filed with the SEC for the
purpose of updating the description. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All reports and other documents we subsequently file pursuant to
Section&nbsp;13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (the Exchange Act) prior to the termination of this offering, including all such documents we may file with the SEC after the date of the initial registration
statement and prior to the effectiveness of the registration statement, but excluding any information furnished to, rather than filed with, the SEC, will also be incorporated by reference into this prospectus and deemed to be part of this prospectus
from the date of the filing of such reports and documents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may request a free copy of any of the documents incorporated by reference in this prospectus (other than
exhibits, unless they are specifically incorporated by reference in the documents) by writing or telephoning us at the following address: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Erasca, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: Corporate
Secretary </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3115 Merryfield Row, Suite 300 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">San Diego, California 92121 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(858) <FONT
STYLE="white-space:nowrap">465-6511</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Exhibits to the filings will not be sent, however, unless those exhibits have specifically been incorporated
by reference in this prospectus or any accompanying prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx63320_3"></A><A NAME="supptoc63320_13"></A>THE COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK
pathway-driven cancers. Molecular alterations in RAS, the most frequently mutated oncogene, and the MAPK pathway, one of the most frequently altered signaling pathways in cancer, account for more than five million new patients diagnosed with cancer
globally each year. Our company was <FONT STYLE="white-space:nowrap">co-founded</FONT> by leading pioneers in precision oncology and RAS targeting to create novel therapies and combination regimens designed to comprehensively shut down the RAS/MAPK
pathway for the treatment of patients with cancer. Our focused RAS/MAPK pipeline comprises modality-agnostic programs aligned with our three therapeutic strategies of: (1)&nbsp;targeting key upstream and downstream signaling nodes in the RAS/MAPK
pathway; (2)&nbsp;targeting RAS directly; and (3)&nbsp;targeting escape routes that emerge in response to treatment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our pipeline enables us to pursue a
systematic, data-driven, portfolio-wide clinical development effort to identify therapeutic approaches with the goal of prolonging survival in numerous patient populations with high unmet medical needs. Our modality-agnostic approach aims to allow
us to selectively and potently target critical signaling nodes with the most appropriate modality, including small and large molecule therapeutics. Our purpose-built pipeline includes three clinical-stage programs (naporafenib, a <FONT
STYLE="white-space:nowrap">pan-RAF</FONT> inhibitor; ERAS-0015, a <FONT STYLE="white-space:nowrap">pan-RAS</FONT> molecular glue; and ERAS-4001, a <FONT STYLE="white-space:nowrap">pan-KRAS</FONT> inhibitor), and
<FONT STYLE="white-space:nowrap">ERAS-12,</FONT> a discovery-stage program (an EGFR D2/D3 biparatopic antibody). We believe our world-class team&#8217;s capabilities and experience, further guided by our scientific advisory board, which includes the
world&#8217;s leading experts in the RAS/MAPK pathway, uniquely position us to achieve our bold mission of erasing cancer.</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were incorporated under the
laws of the state of Delaware on July&nbsp;2, 2018. Our principal executive offices are located at 3115 Merryfield Row, Suite 300, San Diego, California 92121, and our telephone number is (858) <FONT STYLE="white-space:nowrap">465-6511.</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx63320_4"></A><A NAME="supptoc63320_14"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investment in any securities offered pursuant to this prospectus and the applicable prospectus supplement involves risks. You should carefully consider the
risk factors incorporated by reference to our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and any subsequent Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> or Current Reports on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> we file after the date of this prospectus, and all other information contained in or incorporated by reference into this prospectus, as updated by our subsequent filings under the Exchange Act, and the risk
factors and other information contained in the applicable prospectus supplement and any applicable free writing prospectus before acquiring any of such securities. The occurrence of any of these risks might cause you to lose all or part of your
investment in the offered securities. There may be other unknown or unpredictable economic, business, competitive, regulatory or other factors that could have material adverse effects on our future results. Past financial performance may not be a
reliable indicator of future performance, and historical trends should not be used to anticipate results or trends in future periods. If any of these risks actually occurs, our business, financial condition, results of operations or cash flow could
be seriously harmed. This could cause the trading price of our securities to decline, resulting in a loss of all or part of your investment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx63320_5"></A><A NAME="supptoc63320_15"></A>CAUTIONARY NOTE REGARDING
FORWARD-LOOKING STATEMENTS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus and the documents incorporated by reference herein contain forward-looking statements within the meaning
of Section&nbsp;27A of the Securities Act of 1933, as amended (the Securities Act), and Section&nbsp;21E of the Exchange Act. All statements other than statements of historical facts contained in this prospectus and the documents incorporated by
reference herein, including statements regarding our future results of operations and financial position, business strategy, research and development plans, the anticipated timing, costs, design and conduct of our ongoing and planned preclinical
studies and planned clinical trials for our product candidates, the timing and likelihood of regulatory filings and approvals for our product candidates, our ability to commercialize our product candidates, if approved, the impact of global
geopolitical and economic events and war on our business, the pricing and reimbursement of our product candidates, if approved, the potential to develop future product candidates, the potential benefits of current and future licenses, acquisitions
and strategic arrangements with third parties, and our intent to enter into any future strategic arrangements, the timing and likelihood of success, plans and objectives of management for future operations, and future results of anticipated product
development efforts, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any
future results, performance or achievements expressed or implied by the forward-looking statements. This prospectus and the documents incorporated by reference herein also contain estimates and other statistical data made by independent parties and
by us relating to market size and growth and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions and
estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In some cases, you can identify forward-looking statements by terms such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221;
&#8220;should,&#8221; &#8220;expect,&#8221; &#8220;plan,&#8221; &#8220;anticipate,&#8221; &#8220;could,&#8221; &#8220;intend,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplates,&#8221; &#8220;believes,&#8221;
&#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;potential&#8221; or &#8220;continue&#8221; or the negative of these terms or other similar expressions. The forward-looking statements in this prospectus and the documents incorporated by
reference herein are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial and other trends that we believe may affect our business, financial condition
and results of operations. These forward-looking statements speak only as of the date of this prospectus and are subject to a number of known and unknown risks, uncertainties and assumptions, which we discuss in greater detail in the documents
incorporated by reference herein, including under the heading &#8220;Risk Factors&#8221; and elsewhere in this prospectus. The events and circumstances reflected in our forward-looking statements may not be achieved or occur and actual results could
differ materially from those expressed or implied by our forward-looking statements. Moreover, we operate in an evolving environment. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict
all risk factors and uncertainties. Given these risks and uncertainties, you should not place undue reliance on any forward-looking statement. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking
statements contained in this prospectus or the documents incorporated by reference herein, whether as a result of any new information, future events, changed circumstances or otherwise. For all forward-looking statements, we claim the protection of
the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx63320_6"></A><A NAME="supptoc63320_16"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We intend to use the net proceeds from the sale of the securities as set forth in the applicable prospectus supplement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx63320_7"></A><A NAME="supptoc63320_18"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following description summarizes some of the
terms of our capital stock. Because it is only a summary, it does not contain all the information that may be important to you and is subject to and qualified in its entirety by reference to our amended and restated certificate of incorporation and
amended and restated bylaws, which are filed as exhibits to our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and are incorporated by reference herein. We encourage you to read our certificate of incorporation and
our bylaws for additional information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of June&nbsp;30, 2025, our authorized capital stock consisted of 800,000,000 shares of common stock, $0.0001
par value per share, and 80,000,000 shares of preferred stock, $0.0001 par value per share. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of our common stock are entitled to one vote for each share held on all matters submitted to a vote of stockholders, including the election of
directors, and do not have cumulative voting rights. Accordingly, the holders of a majority of the outstanding shares of common stock entitled to vote in any election of directors can elect all of the directors standing for election, if they so
choose, other than any directors that holders of any preferred stock we may issue may be entitled to elect. Subject to supermajority votes for some matters, other matters shall be decided by the affirmative vote of our stockholders having a majority
in voting power of the votes cast by the stockholders present or represented and voting on such matter. Our amended and restated certificate of incorporation and amended and restated bylaws also provide that our directors may be removed only for
cause and only by the affirmative vote of the holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> in voting power of the outstanding shares of capital stock entitled to vote thereon. In addition, the affirmative vote of the
holders of at least <FONT STYLE="white-space:nowrap">two-thirds</FONT> in voting power of the outstanding shares of capital stock entitled to vote thereon is required to amend or repeal, or to adopt any provision inconsistent with, several of the
provisions of our amended and restated certificate of incorporation. See below under the heading &#8220;Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and Bylaws.&#8221; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to preferences that may be applicable to any then outstanding preferred stock, holders of common stock are entitled to receive ratably those
dividends, if any, as may be declared by the board of directors out of legally available funds. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event of our liquidation, dissolution or winding
up, the holders of common stock will be entitled to share ratably in the assets legally available for distribution to stockholders after the payment of or provision for all of our debts and other liabilities, subject to the prior rights of any
preferred stock then outstanding. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of common stock have no preemptive or conversion rights or other subscription rights and there are no
redemption or sinking funds provisions applicable to the common stock. The outstanding shares of common stock are duly authorized, validly issued, fully paid and nonassessable. The rights, preferences and privileges of holders of common stock are
subject to, and may be adversely affected by, the rights of the holders of shares of any series of preferred stock that we may designate and issue in the future. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The transfer agent and
registrar for our common stock is Computershare Trust Company, N.A. The transfer agent and registrar&#8217;s address is 150 Royall Street, Suite 101, Canton, Massachusetts 02021. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the date of this prospectus, we have no outstanding shares of preferred stock. Under the terms of our amended and restated certificate of incorporation,
our board of directors has the authority, without further action by our stockholders, to issue up to 80,000,000 shares of preferred stock in one or more series, to establish from time to time the number of shares to be included in each such series,
to fix the dividend, voting and other rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon, and to increase or decrease the number of shares of any such series,
but not below the number of shares of such series then outstanding. Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of the holders of
the common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in our
control and may adversely affect the market price of the common stock and the voting and other rights of the holders of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Prior to the
issuance of shares of each series, the board of directors is required by the General Corporation Law of the State of Delaware (the DGCL) and our amended and restated certificate of incorporation to adopt resolutions and file a certificate of
designation with the Secretary of State of the State of Delaware. The certificate of designation fixes for each class or series the designations, powers, preferences, rights, qualifications, limitations and restrictions, including dividend rights,
conversion rights, redemption privileges and liquidation preferences. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All shares of preferred stock offered by this prospectus will, when issued, be
fully paid and nonassessable and will not have any preemptive or similar rights. Our board of directors may authorize the issuance of preferred stock with voting or conversion rights that could adversely affect the voting power or other rights of
the holders of the common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a
change in our control and may adversely affect the market price of the common stock and the voting and other rights of the holders of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We
will describe in a prospectus supplement relating to the class or series of preferred stock being offered the following terms: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title and stated value of the preferred stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares of the preferred stock offered, the liquidation preference per share and the offering price
of the preferred stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dividend rate(s), period(s) or payment date(s) or method(s) of calculation applicable to the preferred stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether dividends are cumulative or <FONT STYLE="white-space:nowrap">non-cumulative</FONT> and, if cumulative,
the date from which dividends on the preferred stock will accumulate; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the procedures for any auction and remarketing, if any, for the preferred stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provisions for a sinking fund, if any, for the preferred stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provision for redemption, if applicable, of the preferred stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any listing of the preferred stock on any securities exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms and conditions, if applicable, upon which the preferred stock will be convertible into common stock,
including the conversion price or manner of calculation and conversion period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">voting rights, if any, of the preferred stock; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a discussion of any material or special U.S. federal income tax considerations applicable to the preferred stock;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the relative ranking and preferences of the preferred stock as to dividend rights and rights upon the
liquidation, dissolution or winding up of our affairs; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any limitations on issuance of any class or series of preferred stock ranking senior to or on a parity with the
class or series of preferred stock as to dividend rights and rights upon liquidation, dissolution or winding up of our affairs; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other specific terms, preferences, rights, limitations or restrictions of the preferred stock.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless we specify otherwise in the applicable prospectus supplement, the preferred stock will rank, relating to dividends and upon our
liquidation, dissolution or winding up: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">senior to all classes or series of our common stock and to all of our equity securities ranking junior to the
preferred stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on a parity with all of our equity securities the terms of which specifically provide that the equity securities
rank on a parity with the preferred stock; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">junior to all of our equity securities the terms of which specifically provide that the equity securities rank
senior to the preferred stock. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The term equity securities does not include convertible debt securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Registration Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the Amended and Restated
Stockholders Agreement, dated April&nbsp;15, 2020, by and among us and certain of our stockholders, certain of our stockholders are entitled to the following rights with respect to the registration of their shares for public resale under the
Securities Act. The registration of shares of common stock as a result of the following rights being exercised would enable holders to trade these shares without restriction under the Securities Act when the applicable registration statement is
declared effective. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Demand Registration Rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Form <FONT STYLE="white-space:nowrap">S-1</FONT></I>. If at any time the holders of at least a majority of the registrable securities request in writing
that we effect a registration with respect to all or a part of the registrable securities then outstanding where the aggregate price to the public of the offering is $20.0&nbsp;million or more, we may be required to provide notice to all holders of
registrable securities and to use commercially reasonable efforts to effect such registration; provided, however, that we will not be required to effect such a registration if, among other things, within the preceding 12 months, we have already
effected two registrations for the holders of registrable securities in response to these demand registration rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Form <FONT
STYLE="white-space:nowrap">S-3</FONT></I>. If at any time the holders of the registrable securities request in writing that we effect a registration with respect to all or a part of the registrable securities then outstanding where the price to the
public of the offering is $5.0&nbsp;million or more, we may be required to provide notice to all holders of registrable securities and to use commercially reasonable efforts to effect such registration; provided, however, that we will not be
required to effect such a registration if, among other things, within the preceding 12 months, we have already effected two registrations on Form <FONT STYLE="white-space:nowrap">S-3</FONT> for the holders of registrable securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If the holders requesting registration intend to distribute their shares by means of an underwriting, the underwriter of such offering will have the right to
limit the numbers of shares to be underwritten for reasons related to the marketing of the shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Piggyback Registration Rights </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If at any time we propose to register any shares of our common stock under the Securities Act, subject to certain exceptions, the holders of registrable
securities will be entitled to notice of the registration and to include their </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
shares of registrable securities in the registration. If our proposed registration involves an underwriting, the managing underwriter of such offering will have the right to limit the number of
shares to be underwritten for reasons related to the marketing of the shares. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Indemnification </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our stockholders agreement contains customary cross indemnification provisions, under which we are obligated to indemnify holders of registrable securities in
the event of material misstatements or omissions in a registration statement attributable to us, and they are obligated to indemnify us for material misstatements or omissions attributable to them. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expenses </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ordinarily, other than underwriting discounts
and commissions, we will be required to pay all expenses incurred by us related to any registration effected pursuant to the exercise of these registration rights. These expenses may include all registration and filing fees, printing expenses, fees
and disbursements of our counsel, reasonable fees and disbursements of a counsel for the selling securityholders, blue sky fees and expenses and the expenses of any special audits incident to the registration. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Termination of Registration Rights </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The registration
rights terminate in August 2026. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and Bylaws </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Some provisions of Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws contain provisions that could make
the following transactions more difficult: an acquisition of us by means of a tender offer; an acquisition of us by means of a proxy contest or otherwise; or the removal of our incumbent officers and directors. It is possible that these provisions
could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions which provide for payment of a premium over the market
price for our shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These provisions, summarized below, are intended to discourage coercive takeover practices and inadequate takeover bids. These
provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of the increased protection of our potential ability to negotiate with the proponent of
an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Undesignated Preferred Stock </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ability of our board of
directors, without action by the stockholders, to issue up to 80,000,000 shares of undesignated preferred stock with voting or other rights or preferences as designated by our board of directors could impede the success of any attempt to change
control of us. These and other provisions may have the effect of deferring hostile takeovers or delaying changes in control or management of our company </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stockholder Meetings </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated bylaws
provide that a special meeting of stockholders may be called only by our chairman of the board of directors, chief executive officer or president, or by a resolution adopted by a majority of our board of directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Requirements for Advance Notification of Stockholder Nominations and Proposals </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated bylaws establish advance notice procedures with respect to stockholder proposals to be brought before a stockholder meeting and the
nomination of candidates for election as directors, other than nominations made by or at the direction of the board of directors or a committee of the board of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Elimination of Stockholder Action by Written Consent </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
amended and restated certificate of incorporation and amended and restated bylaws eliminate the right of stockholders to act by written consent without a meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Staggered Board of Directors </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our board of directors is
divided into three classes. The directors in each class serve for a three-year term, with one class being elected each year by our stockholders. This system of electing directors may tend to discourage a third party from attempting to obtain control
of us, because it generally makes it more difficult for stockholders to replace a majority of the directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Removal of Directors </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation provides that no member of our board of directors may be removed from office except for cause and, in
addition to any other vote required by law, upon the approval of not less than two thirds of the total voting power of all of our outstanding voting stock then entitled to vote in the election of directors. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stockholders Not Entitled to Cumulative Voting </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our
amended and restated certificate of incorporation does not permit stockholders to cumulate their votes in the election of directors. Accordingly, the holders of a majority of the outstanding shares of our common stock entitled to vote in any
election of directors can elect all of the directors standing for election, if they choose, other than any directors that holders of our preferred stock may be entitled to elect. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delaware Anti-Takeover Statute </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are subject to
Section&nbsp;203 of the DGCL, which prohibits persons deemed to be &#8220;interested stockholders&#8221; from engaging in a &#8220;business combination&#8221; with a publicly held Delaware corporation for three years following the date these persons
become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an &#8220;interested
stockholder&#8221; is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation&#8217;s voting stock. Generally, a
&#8220;business combination&#8221; includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to
transactions not approved in advance by the board of directors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Choice of Forum </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation provides that, unless we consent in writing to the selection of an alternative forum, the Court of
Chancery of the State of Delaware will be the sole and exclusive forum for the following types of actions or proceedings under Delaware statutory or common law: (i)&nbsp;any derivative action or proceeding brought on our behalf; (ii)&nbsp;any action
asserting a claim of breach of a fiduciary duty or other wrongdoing by any of our directors, officers, employees or agents to us or our stockholders, creditors or other constituents; (iii)&nbsp;any action asserting a claim against us arising
pursuant to any provision of the General </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Corporation Law of the State of Delaware or our amended and restated certificate of incorporation or amended and restated bylaws; (iv)&nbsp;any action to interpret, apply, enforce or determine
the validity of our certificate of incorporation or bylaws; or (v)&nbsp;any action asserting a claim governed by the internal affairs doctrine. The provision would not apply to suits brought to enforce a duty or liability created by the Exchange
Act. Furthermore, our amended and restated certificate of incorporation will also provide that unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall be the exclusive forum for
the resolution of any complaint asserting a cause or causes of action arising under the Securities Act, including all causes of action asserted against any defendant to such complaint. For the avoidance of doubt, this provision is intended to
benefit and may be enforced by us, our officers and directors, the underwriters to any offering giving rise to such complaint, and any other professional entity whose profession gives authority to a statement made by that person or entity and who
has prepared or certified any part of the documents underlying the offering. In any case, stockholders will not be deemed to have waived our compliance with the federal securities laws and the rules and regulations thereunder. The enforceability of
similar choice of forum provisions in other companies&#8217; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our amended and restated certificate of incorporation also provides that any person or entity purchasing or otherwise acquiring any interest in shares of our
capital stock will be deemed to have notice of and to have consented to this choice of forum provision. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Amendment of Charter and Bylaw Provisions
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The amendment of any of the above provisions, except for the provision making it possible for our board of directors to issue preferred stock, would
require approval by holders of at least two thirds of the total voting power of all of our outstanding voting stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The provisions of Delaware law, our
amended and restated certificate of incorporation and our amended and restated bylaws could have the effect of discouraging others from attempting hostile takeovers and, as a consequence, they may also inhibit temporary fluctuations in the market
price of our common stock that often result from actual or rumored hostile takeover attempts. These provisions may also have the effect of preventing changes in the composition of our board of directors and management. It is possible that these
provisions could make it more difficult to accomplish transactions that stockholders may otherwise deem to be in their best interests. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx63320_8"></A><A NAME="supptoc63320_19"></A>DESCRIPTION OF DEBT SECURITIES
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following description, together with the additional information we include in any applicable prospectus supplement or free writing prospectus,
summarizes certain general terms and provisions of the debt securities that we may offer under this prospectus. When we offer to sell a particular series of debt securities, we will describe the specific terms of the series in a supplement to this
prospectus. We will also indicate in the supplement to what extent the general terms and provisions described in this prospectus apply to a particular series of debt securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue debt securities either separately, or together with, or upon the conversion or exercise of or in exchange for, other securities described in this
prospectus. Debt securities may be our senior, senior subordinated or subordinated obligations and, unless otherwise specified in a supplement to this prospectus, the debt securities will be our direct, unsecured obligations and may be issued in one
or more series. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The debt securities will be issued under an indenture between us and a trustee named in the prospectus supplement. We have summarized
select portions of the indenture below. The summary is not complete. The form of the indenture has been filed as an exhibit to the registration statement and you should read the indenture for provisions that may be important to you. In the summary
below, we have included references to the section numbers of the indenture so that you can easily locate these provisions. Capitalized terms used in the summary and not defined herein have the meanings specified in the indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As used in this section only, &#8220;Erasca,&#8221; &#8220;we,&#8221; &#8220;our&#8221; or &#8220;us&#8221; refer to Erasca, Inc., excluding our subsidiaries,
unless expressly stated or the context otherwise requires. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The terms of each series of debt securities will be established by or pursuant to a resolution of our board of directors and set forth or determined in the
manner provided in a resolution of our board of directors, in an officer&#8217;s certificate or by a supplemental indenture. (Section 2.2) The particular terms of each series of debt securities will be described in a prospectus supplement relating
to such series (including any pricing supplement or term sheet). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We can issue an unlimited amount of debt securities under the indenture that may be in
one or more series with the same or various maturities, at par, at a premium, or at a discount. (Section 2.1) We will set forth in a prospectus supplement (including any pricing supplement or term sheet) relating to any series of debt securities
being offered, the aggregate principal amount and the following terms of the debt securities, if applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title and ranking of the debt securities (including the terms of any subordination provisions);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price or prices (expressed as a percentage of the principal amount) at which we will sell the debt
securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any limit on the aggregate principal amount of the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date or dates on which the principal of the securities of the series is payable; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the rate or rates (which may be fixed or variable) per annum or the method used to determine the rate or rates
(including any commodity, commodity index, stock exchange index or financial index) at which the debt securities will bear interest, the date or dates from which interest will accrue, the date or dates on which interest will commence and be payable
and any regular record date for the interest payable on any interest payment date; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the place or places where principal of, and interest, if any, on the debt securities will be payable (and the
method of such payment), where the securities of such series may be surrendered for registration of transfer or exchange and where notices and demands to us in respect of the debt securities may be delivered; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the period or periods within which, the price or prices at which and the terms and conditions upon which we may
redeem the debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any obligation we have to redeem or purchase the debt securities pursuant to any sinking fund or analogous
provisions or at the option of a holder of debt securities and the period or periods within which, the price or prices at which and in the terms and conditions upon which securities of the series shall be redeemed or purchased, in whole or in part,
pursuant to such obligation; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the dates on which and the price or prices at which we will repurchase debt securities at the option of the
holders of debt securities and other detailed terms and provisions of these repurchase obligations; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the denominations in which the debt securities will be issued, if other than denominations of $1,000 and any
integral multiple thereof; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the debt securities will be issued in the form of certificated debt securities or global debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the portion of principal amount of the debt securities payable upon declaration of acceleration of the maturity
date, if other than the principal amount; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the currency of denomination of the debt securities, which may be United States Dollars or any foreign currency,
and if such currency of denomination is a composite currency, the agency or organization, if any, responsible for overseeing such composite currency; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation of the currency, currencies or currency units in which payment of principal of, premium and
interest on the debt securities will be made; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if payments of principal of, premium or interest on the debt securities will be made in one or more currencies or
currency units other than that or those in which the debt securities are denominated, the manner in which the exchange rate with respect to these payments will be determined; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the manner in which the amounts of payment of principal of, premium, if any, or interest on the debt securities
will be determined, if these amounts may be determined by reference to an index based on a currency or currencies or by reference to a commodity, commodity index, stock exchange index or financial index; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any provisions relating to any security provided for the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any addition to, deletion of or change in the Events of Default described in this prospectus or in the indenture
with respect to the debt securities and any change in the acceleration provisions described in this prospectus or in the indenture with respect to the debt securities; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any addition to, deletion of or change in the covenants described in this prospectus or in the indenture with
respect to the debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any depositaries, interest rate calculation agents, exchange rate calculation agents or other agents with respect
to the debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the provisions, if any, relating to conversion or exchange of any debt securities of such series, including if
applicable, the conversion or exchange price and period, provisions as to whether conversion or exchange will be mandatory, the events requiring an adjustment of the conversion or exchange price and provisions affecting conversion or exchange;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other terms of the debt securities, which may supplement, modify or delete any provision of the indenture as
it applies to that series, including any terms that may be required under applicable law or regulations or advisable in connection with the marketing of the securities; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether any of our direct or indirect subsidiaries will guarantee the debt securities of that series, including
the terms of subordination, if any, of such guarantees. (Section 2.2) </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue debt securities that provide for an amount less than their stated principal amount to be due
and payable upon declaration of acceleration of their maturity pursuant to the terms of the indenture. We will provide you with information on the federal income tax considerations and other special considerations applicable to any of these debt
securities in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we denominate the purchase price of any of the debt securities in a foreign currency or currencies
or a foreign currency unit or units, or if the principal of and any premium and interest on any series of debt securities is payable in a foreign currency or currencies or a foreign currency unit or units, we will provide you with information on the
restrictions, elections, general tax considerations, specific terms and other information with respect to that issue of debt securities and such foreign currency or currencies or foreign currency unit or units in the applicable prospectus
supplement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer and Exchange </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each debt
security will be represented by either one or more global securities registered in the name of The Depository Trust Company (DTC or the Depositary), or a nominee of the Depositary (we will refer to any debt security represented by a global debt
security as a &#8220;book-entry debt security&#8221;), or a certificate issued in definitive registered form (we will refer to any debt security represented by a certificated security as a &#8220;certificated debt security&#8221;) as set forth in
the applicable prospectus supplement. Except as set forth under the heading &#8220;Global Debt Securities and Book-Entry System&#8221; below, book-entry debt securities will not be issuable in certificated form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Certificated Debt Securities. You may transfer or exchange certificated debt securities at any office we maintain for this purpose in accordance with the
terms of the indenture. (Section 2.4) No service charge will be made for any transfer or exchange of certificated debt securities, but we may require payment of a sum sufficient to cover any tax or other governmental charge payable in connection
with a transfer or exchange. (Section 2.7) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may effect the transfer of certificated debt securities and the right to receive the principal of, premium
and interest on certificated debt securities only by surrendering the certificate representing those certificated debt securities and either reissuance by us or the trustee of the certificate to the new holder or the issuance by us or the trustee of
a new certificate to the new holder. Global Debt Securities and Book-Entry System. Each global debt security representing book-entry debt securities will be deposited with, or on behalf of, the Depositary, and registered in the name of the
Depositary or a nominee of the Depositary. Please see &#8220;Global Securities.&#8221; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Covenants </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will set forth in the applicable prospectus supplement any restrictive covenants applicable to any issue of debt securities. (Article IV) </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Protection in the Event of a Change of Control </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless
we state otherwise in the applicable prospectus supplement, the debt securities will not contain any provisions which may afford holders of the debt securities protection in the event we have a change in control or in the event of a highly leveraged
transaction (whether or not such transaction results in a change in control) which could adversely affect holders of debt securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Consolidation,
Merger and Sale of Assets </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not consolidate with or merge with or into, or convey, transfer or lease all or substantially all of our properties
and assets to any person (a successor person) unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we are the surviving corporation, or the successor person (if other than Erasca) is a corporation organized and
validly existing under the laws of any U.S. domestic jurisdiction and expressly assumes our obligations on the debt securities and under the indenture, and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">immediately after giving effect to the transaction, no Default or Event of Default shall have occurred and be
continuing. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding the above, any of our subsidiaries may consolidate with, merge into or transfer all or part of its
properties to us. (Section 5.1) </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Events of Default </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;Event of Default&#8221; means with respect to any series of debt securities, any of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">default in the payment of any interest upon any debt security of that series when it becomes due and payable, and
continuance of such default for a period of 30 days (unless the entire amount of the payment is deposited by us with the trustee or with a paying agent prior to the expiration of the <FONT STYLE="white-space:nowrap">30-day</FONT> period);
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">default in the payment of principal of any security of that series at its maturity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">default in the performance or breach of any other covenant or warranty by us in the indenture (other than a
covenant or warranty that has been included in the indenture solely for the benefit of a series of debt securities other than that series), which default continues uncured for a period of 60 days after we receive written notice from the trustee or
Erasca and the trustee receive written notice from the holders of not less than 25% in principal amount of the outstanding debt securities of that series as provided in the indenture; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">certain voluntary or involuntary events of bankruptcy, insolvency or reorganization of Erasca; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other Event of Default provided with respect to debt securities of that series that is described in the
applicable prospectus supplement. (Section 6.1) </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No Event of Default with respect to a particular series of debt securities (except as
to certain events of bankruptcy, insolvency or reorganization) necessarily constitutes an Event of Default with respect to any other series of debt securities. (Section 6.1) The occurrence of certain Events of Default or an acceleration under the
indenture may constitute an event of default under certain indebtedness of ours or our subsidiaries outstanding from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will provide the
trustee written notice of any Default or Event of Default within 30 days of becoming aware of the occurrence of such Default or Event of Default, which notice will describe in reasonable detail the status of such Default or Event of Default and what
action we are taking or propose to take in respect thereof. (Section 6.1) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an Event of Default with respect to debt securities of any series at the
time outstanding occurs and is continuing, then the trustee or the holders of not less than 25% in principal amount of the outstanding debt securities of that series may, by a notice in writing to us (and to the trustee if given by the holders),
declare to be due and payable immediately the principal of (or, if the debt securities of that series are discount securities, that portion of the principal amount as may be specified in the terms of that series) and accrued and unpaid interest, if
any, on all debt securities of that series. In the case of an Event of Default resulting from certain events of bankruptcy, insolvency or reorganization, the principal (or such specified amount) of and accrued and unpaid interest, if any, on all
outstanding debt securities will become and be immediately due and payable without any declaration or other act on the part of the trustee or any holder of outstanding debt securities. At any time after a declaration of acceleration with respect to
debt securities of any series has been made, but before a judgment or decree for payment of the money due has been obtained by the trustee, the holders of a majority in principal amount of the outstanding debt securities of that series may rescind
and annul the acceleration if all Events of Default, other than the <FONT STYLE="white-space:nowrap">non-payment</FONT> of accelerated principal and interest, if any, with respect to debt securities of that series, have been cured or waived as
provided in the indenture. (Section 6.2) We refer you to the prospectus </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
supplement relating to any series of debt securities that are discount securities for the particular provisions relating to acceleration of a portion of the principal amount of such discount
securities upon the occurrence of an Event of Default. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The indenture provides that the trustee may refuse to perform any duty or exercise any of its
rights or powers under the indenture unless the trustee receives indemnity satisfactory to it against any cost, liability or expense which might be incurred by it in performing such duty or exercising such right or power. (Section 7.1(e)) Subject to
certain rights of the trustee, the holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method and place of conducting any proceeding for any remedy available to the
trustee or exercising any trust or power conferred on the trustee with respect to the debt securities of that series. (Section 6.12) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No holder of any
debt security of any series will have any right to institute any proceeding, judicial or otherwise, with respect to the indenture or for the appointment of a receiver or trustee, or for any remedy under the indenture, unless: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">that holder has previously given to the trustee written notice of a continuing Event of Default with respect to
debt securities of that series; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the holders of not less than 25% in principal amount of the outstanding debt securities of that series have made
written request, and offered indemnity or security satisfactory to the trustee, to the trustee to institute the proceeding as trustee, and the trustee has not received from the holders of not less than a majority in principal amount of the
outstanding debt securities of that series a direction inconsistent with that request and has failed to institute the proceeding within 60 days. (Section 6.7) </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Notwithstanding any other provision in the indenture, the holder of any debt security will have an absolute and unconditional right to receive payment of the
principal of, premium and any interest on that debt security on or after the due dates expressed in that debt security and to institute suit for the enforcement of payment. (Section 6.8) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The indenture requires us, within 120 days after the end of our fiscal year, to furnish to the trustee a statement as to compliance with the indenture.
(Section 4.3) If a Default or Event of Default occurs and is continuing with respect to the securities of any series and if it is known to a responsible officer of the trustee, the trustee shall mail to each holder of the securities of that series
notice of a Default or Event of Default within 90 days after it occurs or, if later, after a responsible officer of the trustee has knowledge of such Default or Event of Default. The indenture provides that the trustee may withhold notice to the
holders of debt securities of any series of any Default or Event of Default (except in payment on any debt securities of that series) with respect to debt securities of that series if the trustee determines in good faith that withholding notice is
in the interest of the holders of those debt securities. (Section 7.5) </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modification and Waiver </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We and the trustee may modify, amend or supplement the indenture or the debt securities of any series without the consent of any holder of any debt security:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to cure any ambiguity, defect or inconsistency; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with covenants in the indenture described above under the heading &#8220;Consolidation, Merger and Sale
of Assets&#8221;; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for uncertificated securities in addition to or in place of certificated securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add guarantees with respect to debt securities of any series or secure debt securities of any series;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to surrender any of our rights or powers under the indenture; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to add covenants or events of default for the benefit of the holders of debt securities of any series;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with the applicable procedures of the applicable depositary; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to make any change that does not adversely affect the rights of any holder of debt securities;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to provide for the issuance of and establish the form and terms and conditions of debt securities of any series
as permitted by the indenture; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to effect the appointment of a successor trustee with respect to the debt securities of any series and to add to
or change any of the provisions of the indenture to provide for or facilitate administration by more than one trustee; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">to comply with requirements of the SEC in order to effect or maintain the qualification of the indenture under
the Trust Indenture Act. (Section 9.1) </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may also modify and amend the indenture with the consent of the holders of at least a
majority in principal amount of the outstanding debt securities of each series affected by the modifications or amendments. We may not make any modification or amendment without the consent of the holders of each affected debt security then
outstanding if that amendment will: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the amount of debt securities whose holders must consent to an amendment, supplement or waiver;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the rate of or extend the time for payment of interest (including default interest) on any debt security;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the principal of or premium on or change the fixed maturity of any debt security or reduce the amount of,
or postpone the date fixed for, the payment of any sinking fund or analogous obligation with respect to any series of debt securities; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">reduce the principal amount of discount securities payable upon acceleration of maturity; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">waive a default in the payment of the principal of, premium or interest on any debt security (except a rescission
of acceleration of the debt securities of any series by the holders of at least a majority in aggregate principal amount of the then outstanding debt securities of that series and a waiver of the payment default that resulted from such
acceleration); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make the principal of or premium or interest on any debt security payable in currency other than that stated in
the debt security; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">make any change to certain provisions of the indenture relating to, among other things, the right of holders of
debt securities to receive payment of the principal of, premium and interest on those debt securities and to institute suit for the enforcement of any such payment and to waivers or amendments; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">waive a redemption payment with respect to any debt security. (Section 9.3) </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except for certain specified provisions, the holders of at least a majority in principal amount of the outstanding debt securities of any series may on behalf
of the holders of all debt securities of that series waive our compliance with provisions of the indenture. (Section 9.2) The holders of a majority in principal amount of the outstanding debt securities of any series may on behalf of the holders of
all the debt securities of such series waive any past default under the indenture with respect to that series and its consequences, except a default in the payment of the principal of, premium or any interest on any debt security of that series;
provided, however, that the holders of a majority in principal amount of the outstanding debt securities of any series may rescind an acceleration and its consequences, including any related payment default that resulted from the acceleration.
(Section 6.13) </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Defeasance of Debt Securities and Certain Covenants in Certain Circumstances </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Legal Defeasance</I>. The indenture provides that, unless otherwise provided by the terms of the applicable series of debt securities, we may be discharged
from any and all obligations in respect of the debt securities of any series (subject to certain exceptions). We will be so discharged upon the irrevocable deposit with the trustee, in trust, of money and/or U.S. government obligations or, in the
case of debt securities denominated in a single currency other than U.S. Dollars, government obligations of the government that issued or caused to be issued such currency, that, through the payment of interest and principal in accordance with their
terms, will provide money or U.S. government obligations in an amount sufficient in the opinion of a nationally recognized firm of independent public accountants or investment bank to pay and discharge each installment of principal, premium and
interest on and any mandatory sinking fund payments in respect of the debt securities of that series on the stated maturity of those payments in accordance with the terms of the indenture and those debt securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This discharge may occur only if, among other things, we have delivered to the trustee an opinion of counsel stating that we have received from, or there has
been published by, the U.S. Internal Revenue Service a ruling or, since the date of execution of the indenture, there has been a change in the applicable U.S. federal income tax law, in either case to the effect that, and based thereon such opinion
shall confirm that, the holders of the debt securities of that series will not recognize income, gain or loss for U.S. federal income tax purposes as a result of the deposit, defeasance and discharge and will be subject to U.S. federal income tax on
the same amounts and in the same manner and at the same times as would have been the case if the deposit, defeasance and discharge had not occurred. (Section 8.3) </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Defeasance of Certain Covenants</I>. The indenture provides that, unless otherwise provided by the terms of the applicable series of debt securities, upon
compliance with certain conditions: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we may omit to comply with the covenant described under the heading &#8220;Consolidation, Merger and Sale of
Assets&#8221; and certain other covenants set forth in the indenture, as well as any additional covenants which may be set forth in the applicable prospectus supplement; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any omission to comply with those covenants will not constitute a Default or an Event of Default with respect to
the debt securities of that series (covenant defeasance). </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The conditions include: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">depositing with the trustee money and/or U.S. government obligations or, in the case of debt securities
denominated in a single currency other than U.S. Dollars, government obligations of the government that issued or caused to be issued such currency, that, through the payment of interest and principal in accordance with their terms, will provide
money in an amount sufficient in the opinion of a nationally recognized firm of independent public accountants or investment bank to pay and discharge each installment of principal of, premium and interest on, and any mandatory sinking fund payments
in respect of, the debt securities of that series on the stated maturity of those payments in accordance with the terms of the indenture and those debt securities; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delivering to the trustee an opinion of counsel to the effect that the holders of the debt securities of that
series will not recognize income, gain or loss for United States federal income tax purposes as a result of the deposit and related covenant defeasance and will be subject to United States federal income tax on the same amounts and in the same
manner and at the same times as would have been the case if the deposit and related covenant defeasance had not occurred. (Section 8.4) </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Personal Liability of Directors, Officers, Employees or Securityholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">None of our past, present or future directors, officers, employees or securityholders, as such, will have any liability for any of our obligations under the
debt securities or the indenture or for any claim based on, or in respect or by reason of, such obligations or their creation. By accepting a debt security, each holder waives and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
releases all such liability. This waiver and release is part of the consideration for the issue of the debt securities. However, this waiver and release may not be effective to waive liabilities
under U.S. federal securities laws, and it is the view of the SEC that such a waiver is against public policy. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The indenture and the debt securities, including any claim or controversy arising out of or relating to the indenture or the securities, will be governed by
the laws of the State of New York. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The indenture will provide that we, the trustee and the holders of the debt securities (by their acceptance of the
debt securities) irrevocably waive, to the fullest extent permitted by applicable law, any and all right to trial by jury in any legal proceeding arising out of or relating to the indenture, the debt securities or the transactions contemplated
thereby. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The indenture will provide that any legal suit, action or proceeding arising out of or based upon the indenture or the transactions contemplated
thereby may be instituted in the federal courts of the United States of America located in the City of New York or the courts of the State of New York in each case located in the City of New York, and we, the trustee and the holder of the debt
securities (by their acceptance of the debt securities) irrevocably submit to the <FONT STYLE="white-space:nowrap">non-exclusive</FONT> jurisdiction of such courts in any such suit, action or proceeding. The indenture will further provide that
service of any process, summons, notice or document by mail (to the extent allowed under any applicable statute or rule of court) to such party&#8217;s address set forth in the indenture will be effective service of process for any suit, action or
other proceeding brought in any such court. The indenture will further provide that we, the trustee and the holders of the debt securities (by their acceptance of the debt securities) irrevocably and unconditionally waive any objection to the laying
of venue of any suit, action or other proceeding in the courts specified above and irrevocably and unconditionally waive and agree not to plead or claim any such suit, action or other proceeding has been brought in an inconvenient forum. (Section
10.10). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx63320_9"></A><A NAME="supptoc63320_20"></A>DESCRIPTION OF WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue warrants for the purchase of shares of our common stock or preferred stock or of debt securities. We may issue warrants independently or together
with other securities, and the warrants may be attached to or separate from any offered securities. Each series of warrants will be issued under a separate warrant agreement to be entered into between us and the investors or a warrant agent. The
following summary of material provisions of the warrants and warrant agreements is subject to, and qualified in its entirety by reference to, all the provisions of the warrant agreement and warrant certificate applicable to a particular series of
warrants. The terms of any warrants offered under a prospectus supplement may differ from the terms described below. We urge you to read the applicable prospectus supplement and any related free writing prospectus, as well as the complete warrant
agreements and warrant certificates that contain the terms of the warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The particular terms of any issue of warrants will be described in the
prospectus supplement relating to the issue. Those terms may include: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the number of shares of common stock or preferred stock purchasable upon the exercise of warrants to purchase
such shares and the price at which such number of shares may be purchased upon such exercise; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the designation, stated value and terms (including, without limitation, liquidation, dividend, conversion and
voting rights) of the series of preferred stock purchasable upon exercise of warrants to purchase preferred stock; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the principal amount of debt securities that may be purchased upon exercise of a debt warrant and the exercise
price for the warrants, which may be payable in cash, securities or other property; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date, if any, on and after which the warrants and the related debt securities, preferred stock or common
stock will be separately transferable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the terms of any rights to redeem or call the warrants; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date on which the right to exercise the warrants will commence and the date on which the right will expire;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">United States federal income tax consequences applicable to the warrants; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any additional terms of the warrants, including terms, procedures, and limitations relating to the exchange,
exercise and settlement of the warrants. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of equity warrants will not be entitled to: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">vote, consent or receive dividends; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">receive notice as stockholders with respect to any meeting of stockholders for the election of our directors or
any other matter; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">exercise any rights as stockholders of Erasca. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each warrant will entitle its holder to purchase the principal amount of debt securities or the number of shares of preferred stock or common stock at the
exercise price set forth in, or calculable as set forth in, the applicable prospectus supplement. Unless we otherwise specify in the applicable prospectus supplement, holders of the warrants may exercise the warrants at any time up to the specified
time on the expiration date that we set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A holder of warrant certificates may exchange them for new warrant certificates of different denominations, present them for registration of transfer and
exercise them at the corporate trust office of the warrant agent or any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other office indicated in the applicable prospectus supplement. Until any warrants to purchase debt securities are exercised, the holder of the warrants will not have any rights of holders of the
debt securities that can be purchased upon exercise, including any rights to receive payments of principal, premium or interest on the underlying debt securities or to enforce covenants in the applicable indenture. Until any warrants to purchase
common stock or preferred stock are exercised, the holders of the warrants will not have any rights of holders of the underlying common stock or preferred stock, including any rights to receive dividends or payments upon any liquidation, dissolution
or winding up on the common stock or preferred stock, if any. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx63320_10"></A><A NAME="supptoc63320_21"></A>DESCRIPTION OF UNITS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may issue units consisting of any combination of the other types of securities offered under this prospectus in one or more series. We may evidence each
series of units by unit certificates that we will issue under a separate agreement. We may enter into unit agreements with a unit agent. Each unit agent will be a bank or trust company that we select. We will indicate the name and address of the
unit agent in the applicable prospectus supplement relating to a particular series of units. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following description, together with the additional
information included in any applicable prospectus supplement, summarizes the general features of the units that we may offer under this prospectus. You should read any prospectus supplement and any free writing prospectus that we may authorize to be
provided to you related to the series of units being offered, as well as the complete unit agreements that contain the terms of the units. Specific unit agreements will contain additional important terms and provisions and we will file as an exhibit
to the registration statement of which this prospectus is a part, or will incorporate by reference from another report that we file with the SEC, the form of each unit agreement relating to units offered under this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If we offer any units, certain terms of that series of units will be described in the applicable prospectus supplement, including, without limitation, the
following, as applicable: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the title of the series of units; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">identification and description of the separate constituent securities comprising the units;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the price or prices at which the units will be issued; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the date, if any, on and after which the constituent securities comprising the units will be separately
transferable; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a discussion of certain U.S. federal income tax considerations applicable to the units; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any other terms of the units and their constituent securities. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx63320_11"></A><A NAME="supptoc63320_22"></A>GLOBAL SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Book-Entry, Delivery and Form </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless we indicate
differently in any applicable prospectus supplement or free writing prospectus, the securities initially will be issued in book-entry form and represented by one or more global notes or global securities, or, collectively, global securities. The
global securities will be deposited with, or on behalf of DTC and registered in the name of Cede&nbsp;&amp; Co., the nominee of DTC. Unless and until it is exchanged for individual certificates evidencing securities under the limited circumstances
described below, a global security may not be transferred except as a whole by the depositary to its nominee or by the nominee to the depositary, or by the depositary or its nominee to a successor depositary or to a nominee of the successor
depositary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DTC has advised us that it is: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a limited-purpose trust company organized under the New York Banking Law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a &#8220;banking organization&#8221; within the meaning of the New York Banking Law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a member of the Federal Reserve System; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a &#8220;clearing corporation&#8221; within the meaning of the New York Uniform Commercial Code; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">a &#8220;clearing agency&#8221; registered pursuant to the provisions of Section&nbsp;17A of the Exchange Act.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DTC holds securities that its participants deposit with DTC. DTC also facilitates the settlement among its participants of securities
transactions, such as transfers and pledges, in deposited securities through electronic computerized book-entry changes in participants&#8217; accounts, thereby eliminating the need for physical movement of securities certificates. &#8220;Direct
participants&#8221; in DTC include securities brokers and dealers, including underwriters, banks, trust companies, clearing corporations and other organizations. DTC is a wholly-owned subsidiary of The Depository Trust&nbsp;&amp; Clearing
Corporation (DTCC). DTCC is the holding company for DTC, National Securities Clearing Corporation and Fixed Income Clearing Corporation, all of which are registered clearing agencies. DTCC is owned by the users of its regulated subsidiaries. Access
to the DTC system is also available to others, which we sometimes refer to as indirect participants, that clear through or maintain a custodial relationship with a direct participant, either directly or indirectly. The rules applicable to DTC and
its participants are on file with the SEC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Purchases of securities under the DTC system must be made by or through direct participants, which will
receive a credit for the securities on DTC&#8217;s records. The ownership interest of the actual purchaser of a security, which we sometimes refer to as a beneficial owner, is in turn recorded on the direct and indirect participants&#8217; records.
Beneficial owners of securities will not receive written confirmation from DTC of their purchases. However, beneficial owners are expected to receive written confirmations providing details of their transactions, as well as periodic statements of
their holdings, from the direct or indirect participants through which they purchased securities. Transfers of ownership interests in global securities are to be accomplished by entries made on the books of participants acting on behalf of
beneficial owners. Beneficial owners will not receive certificates representing their ownership interests in the global securities, except under the limited circumstances described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To facilitate subsequent transfers, all global securities deposited by direct participants with DTC will be registered in the name of DTC&#8217;s partnership
nominee, Cede&nbsp;&amp; Co., or such other name as may be requested by an authorized representative of DTC. The deposit of securities with DTC and their registration in the name of Cede&nbsp;&amp; Co. or such other nominee will not change the
beneficial ownership of the securities. DTC has no knowledge of the actual beneficial owners of the securities. DTC&#8217;s records reflect only the identity of the direct participants to whose accounts the securities are credited, which may or may
not be the beneficial owners. The participants are responsible for keeping account of their holdings on behalf of their customers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">So long as the securities are in book-entry form, you will receive payments and may transfer securities only
through the facilities of the depositary and its direct and indirect participants. We will maintain an office or agency in the location specified in the prospectus supplement for the applicable securities, where notices and demands in respect of the
securities and the indenture may be delivered to us and where certificated securities may be surrendered for payment, registration of transfer or exchange. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Conveyance of notices and other communications by DTC to direct participants, by direct participants to indirect participants and by direct participants and
indirect participants to beneficial owners will be governed by arrangements among them, subject to any legal requirements in effect from time to time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Redemption notices will be sent to DTC. If less than all of the securities of a particular series are being redeemed, DTC&#8217;s practice is to determine by
lot the amount of the interest of each direct participant in the securities of such series to be redeemed. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Neither DTC nor Cede&nbsp;&amp; Co. (or such
other DTC nominee) will consent or vote with respect to the securities. Under its usual procedures, DTC will mail an omnibus proxy to us as soon as possible after the record date. The omnibus proxy assigns the consenting or voting rights of
Cede&nbsp;&amp; Co. to those direct participants to whose accounts the securities of such series are credited on the record date, identified in a listing attached to the omnibus proxy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">So long as securities are in book-entry form, we will make payments on those securities to the depositary or its nominee, as the registered owner of such
securities, by wire transfer of immediately available funds. If securities are issued in definitive certificated form under the limited circumstances described below and unless if otherwise provided in the description of the applicable securities
herein or in the applicable prospectus supplement, we will have the option of making payments by check mailed to the addresses of the persons entitled to payment or by wire transfer to bank accounts in the United States designated in writing to the
applicable trustee or other designated party at least 15 days before the applicable payment date by the persons entitled to payment, unless a shorter period is satisfactory to the applicable trustee or other designated party. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Redemption proceeds, distributions and dividend payments on the securities will be made to Cede&nbsp;&amp; Co., or such other nominee as may be requested by
an authorized representative of DTC. DTC&#8217;s practice is to credit direct participants&#8217; accounts upon DTC&#8217;s receipt of funds and corresponding detail information from us on the payment date in accordance with their respective
holdings shown on DTC records. Payments by participants to beneficial owners will be governed by standing instructions and customary practices, as is the case with securities held for the account of customers in bearer form or registered in
&#8220;street name.&#8221; Those payments will be the responsibility of participants and not of DTC or us, subject to any statutory or regulatory requirements in effect from time to time. Payment of redemption proceeds, distributions and dividend
payments to Cede&nbsp;&amp; Co., or such other nominee as may be requested by an authorized representative of DTC, is our responsibility; disbursement of payments to direct participants is the responsibility of DTC; and disbursement of payments to
the beneficial owners is the responsibility of direct and indirect participants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except under the limited circumstances described below, purchasers of
securities will not be entitled to have securities registered in their names and will not receive physical delivery of securities. Accordingly, each beneficial owner must rely on the procedures of DTC and its participants to exercise any rights
under the securities and the indenture. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The laws of some jurisdictions may require that some purchasers of securities take physical delivery of
securities in definitive form. Those laws may impair the ability to transfer or pledge beneficial interests in securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">DTC may discontinue providing
its services as securities depositary with respect to the securities at any time by giving reasonable notice to us. Under such circumstances, in the event that a successor depositary is not obtained, securities certificates are required to be
printed and delivered. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As noted above, beneficial owners of a particular series of securities generally will not receive
certificates representing their ownership interests in those securities. However, if: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">DTC notifies us that it is unwilling or unable to continue as a depositary for the global security or securities
representing such series of securities or if DTC ceases to be a clearing agency registered under the Exchange Act at a time when it is required to be registered and a successor depositary is not appointed within 90 days of the notification to us or
of our becoming aware of DTC&#8217;s ceasing to be so registered, as the case may be; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">we determine, in our sole discretion, not to have such securities represented by one or more global securities;
or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an Event of Default has occurred and is continuing with respect to such series of securities,
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">we will prepare and deliver certificates for such securities in exchange for beneficial interests in the global securities. Any
beneficial interest in a global security that is exchangeable under the circumstances described in the preceding sentence will be exchangeable for securities in definitive certificated form registered in the names that the depositary directs. It is
expected that these directions will be based upon directions received by the depositary from its participants with respect to ownership of beneficial interests in the global securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Euroclear and Clearstream </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If so provided in the
applicable prospectus supplement, you may hold interests in a global security through Clearstream Banking S.A., which we refer to as &#8220;Clearstream,&#8221; or Euroclear Bank S.A./N.V., as operator of the Euroclear System, which we refer to as
&#8220;Euroclear,&#8221; either directly if you are a participant in Clearstream or Euroclear or indirectly through organizations which are participants in Clearstream or Euroclear. Clearstream and Euroclear will hold interests on behalf of their
respective participants through customers&#8217; securities accounts in the names of Clearstream and Euroclear, respectively, on the books of their respective U.S. depositaries, which in turn will hold such interests in customers&#8217; securities
accounts in such depositaries&#8217; names on DTC&#8217;s books. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Clearstream and Euroclear are securities clearance systems in Europe. Clearstream and
Euroclear hold securities for their respective participating organizations and facilitate the clearance and settlement of securities transactions between those participants through electronic book-entry changes in their accounts, thereby eliminating
the need for physical movement of certificates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payments, deliveries, transfers, exchanges, notices and other matters relating to beneficial interests in
global securities owned through Euroclear or Clearstream must comply with the rules and procedures of those systems. Transactions between participants in Euroclear or Clearstream, on one hand, and other participants in DTC, on the other hand, are
also subject to DTC&#8217;s rules and procedures. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Investors will be able to make and receive through Euroclear and Clearstream payments, deliveries,
transfers and other transactions involving any beneficial interests in global securities held through those systems only on days when those systems are open for business. Those systems may not be open for business on days when banks, brokers and
other institutions are open for business in the United States. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cross-market transfers between participants in DTC, on the one hand, and participants in
Euroclear or Clearstream, on the other hand, will be effected through DTC in accordance with the DTC&#8217;s rules on behalf of Euroclear or Clearstream, as the case may be, by their respective U.S. depositaries; however, such cross-market
transactions will require delivery of instructions to Euroclear or Clearstream, as the case may be, by the counterparty in such system in accordance with the rules and procedures and within the established deadlines (European time) of such system.
Euroclear or Clearstream, as the case may be, will, if the transaction meets its settlement requirements, deliver instructions to its U.S. depositary to take action to effect final settlement on its behalf by delivering or receiving interests in the
global securities through DTC, and making or receiving payment in accordance with normal procedures for <FONT STYLE="white-space:nowrap">same-day</FONT> fund settlement. Participants in Euroclear or Clearstream may not deliver instructions directly
to their respective U.S. depositaries. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Due to time zone differences, the securities accounts of a participant in Euroclear or Clearstream
purchasing an interest in a global security from a direct participant in DTC will be credited, and any such crediting will be reported to the relevant participant in Euroclear or Clearstream, during the securities settlement processing day (which
must be a business day for Euroclear or Clearstream) immediately following the settlement date of DTC. Cash received in Euroclear or Clearstream as a result of sales of interests in a global security by or through a participant in Euroclear or
Clearstream to a direct participant in DTC will be received with value on the settlement date of DTC but will be available in the relevant Euroclear or Clearstream cash account only as of the business day for Euroclear or Clearstream following
DTC&#8217;s settlement date. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Other </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
information in this section of this prospectus concerning DTC, Clearstream, Euroclear and their respective book-entry systems has been obtained from sources that we believe to be reliable, but we do not take responsibility for this information. This
information has been provided solely as a matter of convenience. The rules and procedures of DTC, Clearstream and Euroclear are solely within the control of those organizations and could change at any time. Neither we nor the trustee nor any agent
of ours or of the trustee has any control over those entities and none of us takes any responsibility for their activities. You are urged to contact DTC, Clearstream and Euroclear or their respective participants directly to discuss those matters.
In addition, although we expect that DTC, Clearstream and Euroclear will perform the foregoing procedures, none of them is under any obligation to perform or continue to perform such procedures and such procedures may be discontinued at any time.
Neither we nor any agent of ours will have any responsibility for the performance or nonperformance by DTC, Clearstream and Euroclear or their respective participants of these or any other rules or procedures governing their respective operations.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx63320_12"></A><A NAME="supptoc63320_23"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may sell the securities from time to time pursuant to underwritten public offerings, negotiated transactions, block trades or a combination of these
methods or through underwriters or dealers, through agents and/or directly to one or more purchasers. The securities may be distributed from time to time in one or more transactions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at a fixed price or prices, which may be changed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at market prices prevailing at the time of sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at prices related to such prevailing market prices; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">at negotiated prices. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each time that we sell securities covered by this prospectus, we will provide a prospectus supplement or supplements that will describe the method of
distribution and set forth the terms and conditions of the offering of such securities, including the offering price of the securities and the proceeds to us, if applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Offers to purchase the securities being offered by this prospectus may be solicited directly. Agents may also be designated to solicit offers to purchase the
securities from time to time. Any agent involved in the offer or sale of our securities will be identified in a prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a dealer is
utilized in the sale of the securities being offered by this prospectus, the securities will be sold to the dealer, as principal. The dealer may then resell the securities to the public at varying prices to be determined by the dealer at the time of
resale. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an underwriter is utilized in the sale of the securities being offered by this prospectus, an underwriting agreement will be executed with the
underwriter at the time of sale and the name of any underwriter will be provided in the prospectus supplement that the underwriter will use to make resales of the securities to the public. In connection with the sale of the securities, we or the
purchasers of securities for whom the underwriter may act as agent, may compensate the underwriter in the form of underwriting discounts or commissions. The underwriter may sell the securities to or through dealers, and those dealers may receive
compensation in the form of discounts, concessions or commissions from the underwriters and/or commissions from the purchasers for which they may act as agent. Unless otherwise indicated in a prospectus supplement, an agent will be acting on a best
efforts basis and a dealer will purchase securities as a principal, and may then resell the securities at varying prices to be determined by the dealer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any compensation paid to underwriters, dealers or agents in connection with the offering of the securities, and any discounts, concessions or commissions
allowed by underwriters to participating dealers will be provided in the applicable prospectus supplement. Underwriters, dealers and agents participating in the distribution of the securities may be deemed to be underwriters within the meaning of
the Securities Act and any discounts and commissions received by them and any profit realized by them on resale of the securities may be deemed to be underwriting discounts and commissions. We may enter into agreements to indemnify underwriters,
dealers and agents against civil liabilities, including liabilities under the Securities Act, or to contribute to payments they may be required to make in respect thereof and to reimburse those persons for certain expenses. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any common stock will be listed on the Nasdaq Global Select Market, but any other securities may or may not be listed on a national securities exchange. To
facilitate the offering of securities, certain persons participating in the offering may engage in transactions that stabilize, maintain or otherwise affect the price of the securities. This may include over-allotments or short sales of the
securities, which involve the sale by persons participating in the offering of more securities than were sold to them. In these circumstances, these persons would cover such over-allotments or short positions by making purchases in the open market
or by exercising their over-allotment option, if any. In addition, these persons may stabilize or maintain the price of the securities by bidding for or purchasing securities in the open market or by imposing penalty bids, whereby selling
concessions allowed to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
dealers participating in the offering may be reclaimed if securities sold by them are repurchased in connection with stabilization transactions. The effect of these transactions may be to
stabilize or maintain the market price of the securities at a level above that which might otherwise prevail in the open market. These transactions may be discontinued at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may engage in at the market offerings into an existing trading market in accordance with Rule 415(a)(4) under the Securities Act. In addition, we may enter
into derivative transactions with third parties, or sell securities not covered by this prospectus to third parties in privately negotiated transactions. If the applicable prospectus supplement so indicates, in connection with those derivatives, the
third parties may sell securities covered by this prospectus and the applicable prospectus supplement, including in short sale transactions. If so, the third party may use securities pledged by us or borrowed from us or others to settle those sales
or to close out any related open borrowings of stock, and may use securities received from us in settlement of those derivatives to close out any related open borrowings of stock. The third party in such sale transactions will be an underwriter and,
if not identified in this prospectus, will be named in the applicable prospectus supplement (or a post-effective amendment). In addition, we may otherwise loan or pledge securities to a financial institution or other third party that in turn may
sell the securities short using this prospectus and an applicable prospectus supplement. Such financial institution or other third party may transfer its economic short position to investors in our securities or in connection with a concurrent
offering of other securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The specific terms of any <FONT STYLE="white-space:nowrap">lock-up</FONT> provisions in respect of any given offering will
be described in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The underwriters, dealers and agents may engage in transactions with us, or perform services for
us, in the ordinary course of business for which they receive compensation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx63320_13"></A><A NAME="supptoc63320_24"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Latham&nbsp;&amp; Watkins LLP, San Diego, California, will pass upon certain legal matters relating to the issuance and sale of the securities offered hereby
on behalf of Erasca, Inc. Latham&nbsp;&amp; Watkins LLP and certain attorneys in the firm who have rendered, and will continue to render, legal services to us, own shares of our common stock representing in the aggregate less than one percent of the
shares of our common stock outstanding. Additional legal matters may be passed upon for us or any underwriters, dealers or agents, by counsel that we will name in the applicable prospectus supplement. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="tx63320_14"></A><A NAME="supptoc63320_25"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The consolidated financial statements of Erasca, Inc. as of December&nbsp;31, 2024 and 2023, and for the years then ended, have been incorporated by reference
herein and in the registration statement in reliance upon the report of KPMG LLP, independent registered public accounting firm, incorporated by reference herein, and upon the authority of said firm as experts in accounting and auditing. </P>
<P STYLE="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left" style="font-size:10pt;font-weight:bold"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:48pt; margin-bottom:0pt; font-size:18pt; font-family:arial" ALIGN="center"><B><I>$150,000,000 </I></B></P> <P STYLE="font-size:130pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g63320g63r37.jpg" ALT="LOGO" STYLE="width:2.52525in;height:0.422097in;">
 </P> <P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:18pt; font-family:arial" ALIGN="center"><B><I>Common stock </I></B></P>
<P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:24pt; font-family:arial" ALIGN="center"><B>Prospectus supplement </B></P> <P STYLE="font-size:48pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:14pt" ALIGN="center">


<TR>

<TD WIDTH="19%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="25%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="21%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:16pt">
<TD VALIGN="top"><FONT STYLE="font-size:14pt"><B>J.P.&nbsp;Morgan</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-size:14pt"><B>Morgan&nbsp;Stanley</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:16pt; font-family:arial" ALIGN="center"><B>Jefferies</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:14pt; font-family:arial" ALIGN="right"><B>Evercore&nbsp;ISI</B></P></TD></TR>
</TABLE> <P STYLE="margin-top:64pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>&#8195;&#8195;&#8195;, 2026 </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g63320g08k04.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63320g08k04.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1;84&AO=&]S:&]P(#,N,  X0DE-! 0
M    %KR^6" X0DE-! 0      %D< @   @  ' )0  AR<C,U.3 Y,QP"!0!
M36EC<F]S;V9T(%=O<F0@+2!%<F%S8V$@+2!&;W)M(%,M,U]!=6=U<W0@,C R
M,E\Q,S,P-C<X-S8N-U\N9&]C>  X0DE-!"4      ! ?W<G60YS_0%ZJXODU
MR(-C.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
M    4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0    ]P
M<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M   /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E '0
M=0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I;'1I
M;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
M$G!R:6YT3W5T<'5T3W!T:6]N<P   !<     0W!T;F)O;VP      $-L8G)B
M;V]L      !29W--8F]O;       0W)N0V)O;VP      $-N=$-B;V]L
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M8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M      UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M       X0DE- ^T      ! #O_XU  (  0.__C4  @ !.$))300F       .
M             #^    X0DE-! T       0   !:.$))3009       $
M'CA"24T#\P      "0           0 X0DE-)Q        H  0         !
M.$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M   ! #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M      !P  #_____________________________ ^@     ____________
M_________________P/H     /____________________________\#Z
M  #_____________________________ ^@  #A"24T$"       $     $
M  )    "0      X0DE-!!X       0     .$))300:      .#    !@
M            @0   OP    G $4 <@!A ', 8P!A "  +0 @ $8 ;P!R &T
M( !3 "T ,P!? $$ =0!G '4 <P!T "  ,@ P #( ,@!? #$ ,P S #  -@ W
M #@ -P V     0                         !              +\
M@0                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG
M@0    !29VAT;&]N9P   OP    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   ($     4F=H=&QO;F<
M  +\     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
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M!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(!0,,,P$
M A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/PX?%C<S46
MHK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6UQ=7E]59F
M=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U 0 "$0,A
M,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086HK*#!R8U
MPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?569G:&EJ:V
MQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P"OU'J77[OK%F86+U#*:ZS.
MMHQZAD6,8";7,JK;[]E;/S5H?\W?\8__ ')R?_8X_P#I18L
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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MSIE$J23UY&*M2@S:L^_<>/[]=;$+)62K(&D4S5HRM34TZ ;:><+A'',"NT@
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ML!G*Z<<0!,<XLUQ(F?H$ 82]WZDL@MIJ&0_"-SIK<F7QL,Y.Z9L ^Y$ "Y.
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M-<#'%\U(&;4O4M7U\>.4E%NAFC>X@RT_CV25*(@4[A=PE-5-F783"M;2!N
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M8FZ 4<NFB!!/L)@(!E8<A1,( (@4!$1 !';8!$,C@G@YCA;%;F/? YA..G7
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M..I5R.N<'76U&I9RHEKK5VJU$R1#6FG6"(LU>E&].LJ;J,G("1;RD6]2,$8
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M Z^Y,H>&0#N"CL/3.1FSY9*Q6$S>()(3DX)Q*DUBP=R$GU].P$3;LNXOU;>
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&:G$U-?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g63320g63r02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63320g63r02.jpg
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M*"@H*"@H*"@H*"@H_\  $0@ = *T P$B  (1 0,1 ?_$ !P  0 #  ,! 0
M           &!P@#! 4! O_$ %40  $# @(#!PX*!@D$ @,   $  @,$!081
M!Q(A$S%!46&!D0@5%A<B-U)357&3E*'2%$)4=(*2L;*ST2,R-G*#TQ@D5F)S
M=:+!X3-#PO U1&/#XO_$ !H!  (# 0$                % @,$ 0;_Q  Q
M$0 " @$" P8%! ,! 0       0(#!!$2(3%1!1,405)Q%3(S8:%BD;'A(F.!
M0D/_V@ , P$  A$#$0 _ )'C#33B.S8JNUMI:6U.@I*F2&,R1/+BUKB!F0\;
M>9>/V_,5?([/Z&3^8H3I,[X6(_G\WWRHTGL,>IQ3<1#/)M4FE(MOM^8J^1V?
MT,G\Q.WYBKY'9_0R?S%4B*7AJO20\5;ZBV^WYBKY'9_0R?S$[?F*OD=G]#)_
M,52(CPU7I#Q5OJ+;[?F*OD=G]#)_,3M^8J^1V?T,G\Q5(B/#5>D/%6^HMOM^
M8J^1V?T,G\Q:+PO7RW7#=JN%2&-FJJ6*=X8"&ASF G+/@VK#*VW@#]AL/?Y?
M3_AM6'-JA"*<5H;\&V=DFI/4]Y$1+AD43I,TNW_#&-;C:+?36U]-3[GJ.FB>
M7G6C:XYD/ WSQ*+]OS%7R.S^AD_F+PM._?3O7\'\%B@*=U8];A%N/DA%;D6J
MR24O-EM]OS%7R.S^AD_F)V_,5?([/Z&3^8JD16>&J])7XJWU%M]OS%7R.S^A
MD_F+],T^XH![JALSAQ;C(/\ ]BJ)$>&J](>*M]1>ENZH2L:X"XV&GD;PF"<L
M(YB#]JGF&M,V%+P]D51/+;)W; VK;DPG]\$@<^2R>BKGA52Y+0MAG6QYO4WO
M#+'-$R6%[9(WC6:]AS#AQ@K]+'&C_2%><&U;/@LSJBW%V<M%([N'#A+?!/*.
M?-:PPIB&@Q198+G:I=>"38YI_6C<-]KAP$?\I;?C2I^Z&>/DQN6G)GKHB+,:
M0B(@ B(@"&Z6<728-PE)7THB=722MAIVRC-I<=I) (WF@^Q4?V^,6>)M7H'>
M^NSU2M_^'XJIK/"_.&W19O /_=?M/0T-Z2J?3?%QH=VG-:MB;*R9]XU!Z)%K
M]OC%GB;5Z!WOIV^,6>)M7H'>^JH1:/#5>E&?Q-OJ9MO =_;B?"5MNPU1)/%^
ME:W>;(-CAYLP>;)>\J%ZF#$&<=TL$S]K<JN 'BV->/N'G*OI)KZ^[L<1WCV=
MY6I!$14EP1$0 1%&-(.,:'!=B?75GZ2=_<4].#DZ5_%R <)X//DNQBY/1$92
M45N?(]B]WBW6.A?67>LAI*9OQY'99GB WR>0;54&)=/U!3O?%AZV2UA&P3U+
MMS9YPT9DCSY*C\6XHNF*KH^NO%0Z5Y)W.,;&1-\%HX![3PKQ$VJP8Q6L^+%-
MN?.3TKX(LVXZ;L8U3B8)Z.B:>""G!R^OK+RCI7QL7ZW7Z;/B$,>71JJ#HM2H
MK7**,COM?_IEDV_35C*D<#+64U6T?%GIV_\ CJE3K#O5 P2.;'B&T.ASWYJ-
M^L/J.V^TK/B*$L6J7D3AE6PY2-PX:Q/9L2TN[V2X0U30.Z:TY/9^\T[1SA>P
ML(6RX5EKK8ZNVU,M+4QG-LD3BUP6B=%&F)EZG@L^)@R&XR$1PU31DR=QV .'
MQ7'H/)PK[\*4%NAQ0QQ\Z-CVSX,N9$183>$1$ %QU$\5-"^:HE9%"P9N>]P:
MUHXR3O*(Z1=(-JP51CX4?A-QD;G#1QNR<[E<?BMY>C-9@QKCF^8OJ2^ZU3A3
M YQTL1+8F<W">4YE:J,65O'DC)?EPIX<V:!Q1ILPS:'/AMQENU0W9_5^YC!_
M?._YP"JSO.GG$E4YPMM+0T$? =4RO'.3E_I51(F4,.J'EJ+)YML_/3V)E6:3
M\959)DO]4W/@B#8_N@+H]GF*];6[([MG\Z?^:C:*Y507)(H=LWS;)E1Z3\94
MC@8[_5.RX)0V3[P*E=ET\XCI'-;<Z6AN$?"=4Q//.-G^E5$BC*BN7.*)QR+8
M\I,U;A/3/AF]N9#6R26FJ=LU:G+<R>20;.G)65&]LC&OC<U['#,.:<P1QA8(
M4YT=Z2;Q@ZI9$R1U9:B[])1R.V <)8?BGV'A"QW8"TUK_8VT]H/72S]S8"+B
MI)OA%+#-J/CW1@?J/&3FYC/(\JY4K&H1$0 1$0! ],6-I<%8=AGH1"^XU,PC
MA;*"6Y#:YQ (WAD/.X*F>WQBSQ-J] [WUTM/V(^OF.IJ6%^M2VQOP9F1V%^>
M;ST[/HJM4YQ\:'=IS6K8ER<J?>-0>B1:_;XQ9XFU>@=[Z_46GG%(E89:>UNC
M!&L!"X$CAVZZJ9%=X:KTE'B;?4S>-NJX;A04U93.UH*B-LL;N-KAF/M7857=
M3M?NNN!10ROSJ+9(83GO[F>Z8?M'T5:*1V0V3<>@]JGWD%+J$1% L"(B "(B
M "(B "(B "(B "(B ,5Z3.^%B/Y_-]\J-*2Z3.^%B/Y_-]\J-+T=?R+V/-6?
M._<+MT]MKJF(24]%4RQG>>R)S@><!=1:SZGSO7V[_%F_$<J\B[N8[M-2W&I[
MZ>W70RWUFNGDVM] [\DZS73R;6^@=^2W4BQ?$7Z3;\-7J_!A7K-=/)M;Z!WY
M)UFNGDVM] [\ENI$?$7Z0^&KU?@PKUFNGDVM] [\EL[ ;'1X)L#)&N8]M! '
M-<,B#N;=A7N(L^1DNY)::&C'Q50V]==0B(LIK,B:=^^G>OX/X+% 5/M._?3O
M7\'\%B@*]#1]./LCSE_U)>["]BS88OEZIGU%HM5960,?N;I((BX!V0.68X<B
M.E>.M-=3#^PUQ_S%_P"'&HY%KJAN1+&J5T]K*,[ ,6_V<NGJ[OR70N&%[];H
MS)7V6XT\8WWRTSVM'.1DMPHL*[0EYQ-[[.CY2,#(M,Z9M%]#<[557JQ4S*:Z
M4[3++%$W)M0T;3L'QLMN8W]X\:S,M]-T;HZH7WT2IEMD%8^@W&#\-8MBI*B0
MBV7%S89FD[&/.QC^8[#R$\2KA?02"""01O$*<X*<7%^9"N;KDI+R-\(O&P5<
MW7C"5GN$ASDJ*6-[S_?U1K>W->RO.M:/1GI(O<M4$1%PZ%UKG6PVVW55=5.U
M8*:)TLAXFM!)^Q=E53U1M_ZUX*9;8GY5%SE$9 .W<V]TX].J.<JRJ'>34>I7
M;/NX.70S5?;E->+S77*J.<U5,Z9W)F2<O,-Y=%$7H4M."/.-Z\6$7W(Y Y'(
M[Q7Q=.$DT<7XX:QG:[D7%L+)0R;_  W=R[V'/F6U000"""#O$+ RV%H8O_9!
MH_MTLC]:II1\$FX]9F0!/G;JGG2WM"O@IH9]G6<76_<FZ(B5C4(B( $@ DG(
M#:25C;2KBR3%V+JJK:\FAA)AI&< C!_6\[CMY^1:@TI7)UJT>WZJC=JR"F=&
MTC@+^X!_U+%Z9]GUKC-BOM&Q\(+W"(N_8;<^[WNWVZ)VJ^KG9 '>#K. S]J9
M-Z<18EJ]$?+1:+C>*C<+50U-9*-]L$9>1Y\MY2?M68TW'=.L%1J\6NS6Z-;-
M:QPW8K?ARTPVZTT[(:>,9;!W3SPN<>$GC7II7/M"6O\ BN UAV='3_)\3#%W
ML-VLSM6[6VLH\SD#/"Y@/F)&17FK>T\,51"^*>-DL3QDYCVAP<.(@JJ,>:%+
M/>8Y*G#P9:KAOB-H_02'B+?B^<;.16U9\7PFM"JWL^45K!ZF8%=_4X8,^%UT
MF)J^/."F)CI X?K2?&?]$;!RGD5<4&![S/C2##-32OIJY\F3]89AK-\R9[Q;
MD"<QOK8=BM=+9+126V@9J4U-&(V#S<)Y2=IY2NYEZC#;%\_X(X6.Y3W2\OY.
M\B(E Y"A>E/'-/@FQ&8!LMRJ,V4L!X3PN=_='MV!3"JJ(J6FFJ*AXCAB89'O
M=O-:!F2>8+%^D/%$^+L45=SF+A"3N=/&?^W$"=4>?A/*2M6)1WLN/)&3+O[F
M'#FSQ;M<JN[W&>NN,[ZBKG=K22/.TG_8<G NHB)VEIP0B;UXL(N_8[/7WVY1
M4%III*FJE/<L8.#C)W@.4K0&"]!%NI(HZC%,[JZI.TTT+BR)O(7?K.]BJMOA
M5\S+J<>=WRHS@NPVAJWLUF4L[F\8C)"VY:,.66SL#;7:J*ERX8H6AQ\YRS*]
M58GVCTB;5V:_.7X,#N:6N+7 @C?!"^+=MQM=!<HC'<:&EJHSL+9XFO'M"KC%
M>A+#EV8^2TB2TU9V@Q=W$3RL.]S$*<,^#^9:$)]GS7RO4RRIAHEL'9%CRUTC
MV:U/&_X1/Q:C-N1\YR'.NOCC UZP=5".ZT^M3O.455%W44G/P'D.15Q=3#8-
MPM5ROLS.[J7BFA)\!NUQ'(7$#Z*OON4:G.+***7*U0DB[T1$B'X1$0 7A8ZO
MS,-83N=U>1KP1'<@?C2'8P=)"]U4!U3N(]:6W8>@?L:/A=0!Q[0P?>/.%=CU
M]Y8HE.19W5;D41-*^:9\LKB^1[BYSCODG:2OPB+T!YT(OK@6N+7 @@Y$'@7Q
M %H=3Q?NM..VT4K\J>YQF @[VZ#NF'V$?26J5@V@JYJ"NIZNF=J3P2-EC=Q.
M:<P>D+<>'[I#>K'07.F_Z55"V4#BS&9',=G,E.?7I)3ZC?LZS6+@_([Z(B7C
M$(B( (B( (B( (B( (B( (B( Q7I,[X6(_G\WWRHTI+I,[X6(_G\WWRHTO1U
M_(O8\U9\[]PM9]3YWK[=_BS?B.63%H+1!I)PQAS M';;O7OAK(WR.<P02/R!
M>2-H&6\5FS82E7I%:\33@SC"QN3TX%[HJ[[<V"?*DOJLONIVYL$^5)?59?=2
MKN+/2_V&W?U>I?N6(BKOMS8)\J2^JR^ZG;FP3Y4E]5E]U'<6>E_L'?U>I?N6
M(BA%ETIX3O-TIK=;[C))5U#]2-AIY&YGSD9!3=0E"4.$EH61G&?&+U"(BB2,
MB:=^^G>OX/X+% 5/M._?3O7\'\%B@*]#1]./LCSE_P!27NPM-=3#^PUQ_P Q
M?^'&LRK374P_L-<?\Q?^'&J,[Z3+\#ZQ;Z(B2CP$ @@C,%81N\;(KK6QPY;F
MR=[6Y<0<<EKG2IC>DP?AZ=^[,-UG864D /=%QV:Y'@C?]BQX2222<R=I*:=G
MP:3D^3%/:,TVHKFCXB(F0M-BZ&-;M8V#6W]Q=T:[LE-%X>!+>ZU8-LE#(-62
M&DB:\<3M4%WMS7N+SECUFW]STM2T@E]@B(H$PLFZ?+_UZQ_4P1/UJ:W-%*S+
M>UAF7GZQ(^B%IO%]ZCP]AFY767+*EA<]H/QG[S1SN("Q#4325$\DTSR^61Q>
M]QWR2<R4Q[/KU;FQ;VA9I%07F<:(I/HSL79'C>TV]S=:!THDF'!N;.Z<.<#+
MG3.4E%.3\A7&+DU%>9/=(>!>M&A_#=:V+*KI3K59RVY3;=O[I#6\ZIM;BQ=9
MV7_#%SM3P/ZU YC2>!V6;3S$ K$$T;X97Q2M+9&.+7-.^"-A"R85SLBT^>O\
MFO-I5<DURT_@_"N;J9K_ / \1UMDF?E%71[K$#XQFT@>=N?U0J97I8;NLMCO
MU!<Z?/=*69LH'A ':.<9CG6BZOO(.)GIL[N:D;G1<-#515U%3U=,\/@GC;+&
MX<+7#,'H7,O/'HPB(@"O]/37.T6WC5X#"3YMU8LC+;^-;1U^PE=K8W+7J:=[
M(\_#RS;_ *@%B*1CHY',D:6O:2US2,B".!-NSY+8U]Q/VC%[U+['Y7>L-Q?:
M+W;[C$W6?23LG#?"U7 Y<^2Z*+>UKP,">CU1N?#E\H,16B"Y6J=LU-*,]AVM
M/"UPX".)>DL/8:Q+=\-5?PFR5\U+(?U@TYM?^\T[#SA7)A73\>XAQ1;<^ U-
M']I8X_8>9*+<&<>,.*'%.?"2TGP9?J+P,-8QL&)8P;-<Z>H?EF82=60>=AR/
ML7OK$XN+T9NC)26J9Q&E@=5MJC#&:EK#&V4M&L&D@EN>_EF!LY%RHBX="(B
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M(B(N%YBO29WPL1_/YOOE1I2729WPL1_/YOOE1I>CK^1>QYJSYW[A$13(!$1
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M9^<C/G4G7G91<6XOR/21DI)27F%ES37I"GO.*8J:R53XZ&U29Q2Q.RUYAOR
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M;JS+C.6UO. H:1D<BF49QFM8O462A*#TDM B(I$0B+ZQKGN#6-+G$Y  9DH
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MW"QT;I7;\D;-R>>4N9D3SHBE&3CQ3T(RBI+1K4B]1H.P?*XED=?".)E1F/\
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2(BX="(B "(B "(B "(B /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g63320g63r37.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g63320g63r37.jpg
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M-C="4H*4L;(C5F)RP<(D0U.BTS-$\#1S=>$E5&3_Q  : 0 " P$!
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MM4#>Y.@ ['=1*ERP."0002"-H(5KZ.M,MTL+XJ._NDN=L^3KN.<T0\#C\H>
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M'3/66^:&W8LD?5T)(8RL.V6+^;[8]?3P+!=@.*UKYF^CU!2>S9R-(H@.8!'
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M<O7-5;Z%WL6C4XJ6/9%M;+.2BZW:Y>N:JWT+O8G:Y>N:JWT+O8C5$=Q9XO\
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M<F%KK09?^SNCZA$C]:IH<Z.3E[W+5/FEOK615<.YIO\ \!Q756B5^45QBUF
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M9L5Y>).RS:@NIG1%HON>[;S[6>A;[4[GNV\^UGH6^U:>-I[F7@;NQ)-S_?\
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MC+G#D891:9ON@7#]8YS[36UEN<>!IRF8.HY._P!RAEPW/]]B)^ 76W5#>+?
M^(GJR</6MT<RJ7SH8)85T?C4IE%9TNA#&+#WL%%)X6U(_KDD.@_&,AR?#0Q>
M%]2/Z JSB*O)%?#6^+*Q173;=S]>97#LC>*"G;Q[RU\I'E#?S4ZP]H,PS;G-
MDN4E5=)1Q2.WN/S6[?*2JI9M4?G4MAA72^-#..',.W7$=:*6RT,U5+LUBT=Z
MP<KG'8!TK1^B_1#189?%<KTZ.NN[<G, &<4!_AS^4[PGJ'&K+MMOH[72MIK;
M2P4M.W@CA8&-'4%ZE@OS96?UCR0QHPH5?VES852[HW$G8O"4=I@?E4W-^J[(
M[1$W:[RG5'1FK:5;:0-%4&-+[V2K;Q4PZL38HX61-+6-&9XSQDD]:HQW"-BE
M/HB[(4Y5N,.K,GHM%]SW;>?:ST+?:G<]VWGVL]"WVIMQM/<4<#=V,Z $D #,
ME;6T=6(8<P7:;:6ZLL<(=-_[CN^=ZR1U* 6;0/:K==J.MDNU54-IYFR[R^)H
M:_5.>1\&Q7$L69D1M2C#H;L+&E4W*?4(B+ , B(@ B(@#+VZ/L/8W&L=RB9E
M!<H0\GBWQG>N]6H>M5.MFZ1L$4>.+53T=9/)3.@EWUDT;0XC801MXCF/(%7O
M<]VWGVL]"WVIMCYD(UJ,WS0HR,*R5CE!<F9T7OL%SFLM[H;E3']K2S-F:.7(
MYY=? K\[GNV\^UGH6^U.Y[MO/M9Z%OM5KS:6M&RE85Z>J1<UNJX;A04U93.U
MX*B-LL;N5KAF/45Z%QL'6/M;P[1VD5<E6RE!8R61H#M7,D#9R9Y=2[*2RT3>
9G0>1U:6O4(B+P]"(B "(B "(B "(B /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
